Document And Entity Information
Document And Entity Information | 9 Months Ended |
Jun. 30, 2022 | |
Document Information [Line Items] | |
Entity Central Index Key | 0001537561 |
Entity Registrant Name | Arch Therapeutics, Inc. |
Amendment Flag | true |
Document Fiscal Period Focus | Q3 |
Document Fiscal Year Focus | 2022 |
Document Type | S-1/A |
Entity Incorporation, State or Country Code | NV |
Entity Tax Identification Number | 46-0524102 |
Entity Address, Address Line One | 235 Walnut St., Suite 6 |
Entity Address, City or Town | Framingham |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 01702 |
City Area Code | 617 |
Local Phone Number | 431-2313 |
Entity Filer Category | Non-accelerated Filer |
Entity Small Business | true |
Entity Emerging Growth Company | false |
Amendment Description | This Amendment No. 1 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on August 19, 2022 (File No. 333-267004) (this "Amendment No. 1") is being filed solely (i) to file the Inline XBRL data to the Financial Statements and Notes thereto and (ii) to update the Consolidated Statements of Cash Flows (Unaudited) in the Financial Statements to remove the six-month period ended March 31, 2022 and 2021 and to include the nine-month period ended June 30, 2022 and 2021. Accordingly, this Amendment No. 1 consists solely of the facing page, Part II, Item 16, and the signature page. This Amendment No. 1 does not modify any provision of the prospectus that forms a part of the Registration Statement. Accordingly, a preliminary prospectus has been omitted. |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Sep. 30, 2021 | Sep. 30, 2020 |
Current assets: | ||
Cash | $ 2,266,639 | $ 959,309 |
Inventory | 1,093,765 | 967,993 |
Prepaid expense and other current assets | 307,341 | 215,673 |
Total current assets | 3,667,745 | 2,142,975 |
Long-term assets: | ||
Property and equipment, net | 5,240 | 4,552 |
Other assets | 3,500 | 3,500 |
Total long-term assets | 8,740 | 8,052 |
Total assets | 3,676,485 | 2,151,027 |
Long-term liabilities: | ||
Accounts payable | 408,083 | 342,050 |
Accrued expenses and other liabilities | 319,464 | 248,968 |
Current portion of derivative liability | 1,000,000 | 0 |
Current portion of PPP Loan | 0 | 37,442 |
Total current liabilities | 1,727,547 | 628,460 |
Long-term portion of PPP loan | 0 | 138,858 |
Accrued interest | 167,137 | 17,781 |
Derivative liability, net of current portion | 1,207,475 | 2,316,419 |
Total long-term liabilities | 2,974,612 | 3,023,058 |
Total liabilities | 4,702,159 | 3,651,518 |
Commitments and contingencies | ||
Stockholders’ deficit: | ||
Common stock, $0.001 par value, 800,000,000 shares authorized; 237,169,770 shares issued as of June 30, 2022 and September 30, 2021, respectively, and 236,994,770 and 236,719,770 shares outstanding as of June 30, 2022 and September 30, 2021, respectively | 236,720 | 193,045 |
Additional paid-in capital | 48,534,525 | 41,862,901 |
Accumulated deficit | (49,796,919) | (43,556,437) |
Total stockholders’ deficit | (1,025,674) | (1,500,491) |
Total liabilities and stockholders’ deficit | 3,676,485 | 2,151,027 |
Convertible Notes Payable Series One [Member] | ||
Long-term liabilities: | ||
Convertible notes | 550,000 | 550,000 |
Convertible Notes Payable Series Two [Member] | ||
Long-term liabilities: | ||
Convertible notes | $ 1,050,000 | $ 0 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parentheticals) - $ / shares | Jun. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2020 |
Common Stock, Par Value (in dollars per share) | $ 0.001 | $ 0.001 | $ 0.001 |
Common Stock, Shares Authorized (in shares) | 800,000,000 | 800,000,000 | 800,000,000 |
Common Stock, Shares Issued (in shares) | 237,169,770 | 237,169,770 | 193,044,766 |
Common Stock, Shares Outstanding (in shares) | 236,994,770 | 236,719,770 | 193,044,766 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) | 12 Months Ended | |
Sep. 30, 2021 | Sep. 30, 2020 | |
Revenue | $ 11,565 | $ 0 |
Operating expenses: | ||
Cost of revenues | 26,282 | 0 |
Selling, general and administrative expense | 5,009,323 | 3,741,020 |
Research and development expense | 1,353,084 | 1,611,094 |
Total costs and expenses | 6,388,689 | 5,352,114 |
Loss from operations | (6,377,124) | (5,352,114) |
Other income: | ||
Interest expense | (150,531) | (18,534) |
Other Nonoperating Income (Loss) Debt Forgiveness Amount | 178,229 | 0 |
Decrease to fair value of derivative | 108,944 | 679,271 |
Total other income | 136,642 | 660,737 |
Net loss | $ (6,240,482) | $ (4,691,377) |
Loss per share - basic and diluted | ||
Net loss per common share - basic and diluted (in dollars per share) | $ (0.03) | $ (0.02) |
Weighted common shares - basic and diluted (in shares) | 220,001,412 | 188,051,683 |
Consolidated Statements of Chan
Consolidated Statements of Changes in Stockholders' Deficit - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance (in shares) at Sep. 30, 2019 | 172,612,233 | |||
Balance at Sep. 30, 2019 | $ 172,612 | $ 37,885,151 | $ (38,865,060) | $ (807,297) |
Net loss | $ 0 | 0 | (4,691,377) | (4,691,377) |
Shares issued for the exercise of warrants (in shares) | 5,181,819 | |||
Shares issued for the exercise of warrants | $ 5,182 | 927,546 | 0 | 932,728 |
Issuance of common stock and warrants, net of financing costs (in shares) | 14,285,714 | |||
Issuance of common stock and warrants, net of financing costs | $ 14,286 | 2,152,876 | 0 | 2,167,162 |
Vesting of restricted stock (in shares) | 965,000 | |||
Vesting of restricted stock | $ 965 | (965) | 0 | 0 |
Stock-based compensation expense | $ 0 | 898,293 | 0 | $ 898,293 |
Balance (in shares) at Sep. 30, 2020 | 193,044,766 | 193,044,766 | ||
Balance at Sep. 30, 2020 | $ 193,045 | 41,862,901 | (43,556,437) | $ (1,500,491) |
Shares issued for the exercise of warrants (in shares) | 0 | |||
Vesting of restricted stock | (550) | 0 | $ 0 | |
Stock-based compensation expense | 372,196 | 0 | 372,196 | |
Balance at Jun. 30, 2021 | 48,410,655 | (48,031,742) | $ 615,633 | |
Balance (in shares) at Sep. 30, 2020 | 193,044,766 | 193,044,766 | ||
Balance at Sep. 30, 2020 | $ 193,045 | 41,862,901 | (43,556,437) | $ (1,500,491) |
Net loss | $ 0 | 0 | (6,240,482) | (6,240,482) |
Issuance of common stock and warrants, net of financing costs (in shares) | 43,125,004 | |||
Issuance of common stock and warrants, net of financing costs | $ 43,125 | 6,176,108 | 0 | 6,219,233 |
Stock-based compensation expense | $ 0 | 496,066 | 0 | 496,066 |
Vesting of restricted stock issued (in shares) | 550,000 | |||
Vesting of restricted stock issued | $ 550 | (550) | $ 0 | |
Balance (in shares) at Sep. 30, 2021 | 236,719,770 | 236,719,770 | ||
Balance at Sep. 30, 2021 | $ 236,720 | 48,534,525 | (49,796,919) | $ (1,025,674) |
Balance at Mar. 31, 2021 | 48,316,799 | (46,501,837) | 2,051,682 | |
Stock-based compensation expense | 93,856 | 0 | 93,856 | |
Balance at Jun. 30, 2021 | 48,410,655 | (48,031,742) | 615,633 | |
Balance at Sep. 30, 2021 | $ 236,720 | 48,534,525 | (49,796,919) | $ (1,025,674) |
Shares issued for the exercise of warrants (in shares) | 0 | |||
Vesting of restricted stock | (275) | 0 | $ 0 | |
Stock-based compensation expense | 397,470 | 0 | $ 397,470 | |
Balance (in shares) at Jun. 30, 2022 | 236,994,770 | |||
Balance at Jun. 30, 2022 | 48,931,720 | (53,184,214) | $ (4,015,499) | |
Balance at Mar. 31, 2022 | 48,841,040 | (52,137,384) | (3,059,424) | |
Vesting of restricted stock | (75) | 0 | 0 | |
Stock-based compensation expense | 90,755 | 0 | $ 90,755 | |
Balance (in shares) at Jun. 30, 2022 | 236,994,770 | |||
Balance at Jun. 30, 2022 | $ 48,931,720 | $ (53,184,214) | $ (4,015,499) |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 9 Months Ended | 12 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Sep. 30, 2021 | Sep. 30, 2020 | |
Cash flows from operating activities: | ||||
Net loss | $ (3,387,295) | $ (4,475,305) | $ (6,240,482) | $ (4,691,377) |
Adjustments to reconcile net loss to cash used in operating activities: | ||||
Depreciation | 2,397 | 1,788 | 2,587 | 6,926 |
Stock-based compensation | 397,470 | 372,196 | 496,066 | 898,293 |
(Decrease) to fair value of derivative | (108,944) | (679,271) | ||
Inventory obsolescence charge | 248,073 | 181,988 | 181,988 | 60,385 |
Gain on forgiveness of loan | 0 | (178,229) | (178,229) | 0 |
(Increase) decrease in: | ||||
Inventory | (582,572) | (42,215) | (307,760) | (681,731) |
Prepaid expenses and other current assets | 223,854 | (163,135) | (91,668) | 147,032 |
Increase (decrease) in: | ||||
Accounts payable | 1,288,130 | (64,853) | 66,033 | (191,505) |
Accrued interest | 119,671 | 110,956 | 151,285 | 0 |
Accrued expenses and other liabilities | (96,370) | (80,324) | 70,496 | 86,493 |
Net cash used in operating activities | (2,786,642) | (4,446,077) | (5,958,628) | (5,044,755) |
Cash flows from investing activities: | ||||
Purchases of property and equipment | 0 | (3,275) | (3,275) | (2,455) |
Net cash used in investing activities | 0 | (3,275) | (3,275) | (2,455) |
Cash flows from financing activities: | ||||
Proceeds received from series 2 convertible notes | 0 | 1,050,000 | 1,050,000 | 550,000 |
Proceeds received from PPP loan | 0 | 176,300 | ||
Proceeds from issued common stock and warrants, net of financing costs | 0 | 6,219,233 | 6,219,233 | 2,167,162 |
Proceeds from exercise of warrants | 0 | 932,728 | ||
Net cash provided by financing activities | 575,000 | 7,269,233 | 7,269,233 | 3,826,190 |
Net increase (decrease) in cash | 1,307,330 | (1,221,020) | ||
Cash, beginning of year | 2,266,639 | 959,309 | 959,309 | 2,180,329 |
Cash, end of period | 2,266,639 | 959,309 | ||
Non-cash financing activities: | ||||
Issuance of restricted stock | 0 | 965 | ||
Issuance of restricted stock for services | $ 29,831 | $ 103,750 | 103,750 | 93,500 |
Series J Warrants cost | $ 0 | $ 219,737 |
Consolidated Balance Sheets (Cu
Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Jun. 30, 2022 | Sep. 30, 2021 |
Cash | $ 54,997 | $ 2,266,639 |
Inventory | 1,428,264 | 1,093,765 |
Prepaid expense and other current assets | 83,487 | 307,341 |
Total current assets | 1,566,748 | 3,667,745 |
Long-term assets: | ||
Property and equipment, net | 2,843 | 5,240 |
Other assets | 3,500 | 3,500 |
Total long-term assets | 6,343 | 8,740 |
Total assets | 1,573,091 | 3,676,485 |
Current liabilities: | ||
Accounts payable | 1,696,213 | 408,083 |
Accrued expense and other liabilities | 223,094 | 319,464 |
Current portion of derivative liability | 0 | 1,000,000 |
Total current liabilities | 1,919,307 | 1,727,547 |
Long-term liabilities: | ||
Advances from investors | 575,000 | 0 |
Accrued interest | 286,808 | 167,137 |
Derivative liability, net of current portion | 1,207,475 | 1,207,475 |
Total long-term liabilities | 3,669,283 | 2,974,612 |
Total liabilities | 5,588,590 | 4,702,159 |
Commitments and contingencies | ||
Stockholders’ deficit: | ||
Common stock, $0.001 par value, 800,000,000 shares authorized; 237,169,770 shares issued as of June 30, 2022 and September 30, 2021, respectively, and 236,994,770 and 236,719,770 shares outstanding as of June 30, 2022 and September 30, 2021, respectively | 236,995 | 236,720 |
Additional paid-in capital | 48,931,720 | 48,534,525 |
Accumulated deficit | (53,184,214) | (49,796,919) |
Total stockholders’ deficit | (4,015,499) | (1,025,674) |
Total liabilities and stockholders’ deficit | 1,573,091 | 3,676,485 |
Series 1 Convertible Notes [Member] | ||
Long-term liabilities: | ||
Convertible notes | 550,000 | 550,000 |
Series 2 Convertible Notes [Member] | ||
Long-term liabilities: | ||
Convertible notes | $ 1,050,000 | $ 1,050,000 |
Consolidated Balance Sheets (_2
Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares | Jun. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2020 |
Common Stock, Par Value (in dollars per share) | $ 0.001 | $ 0.001 | $ 0.001 |
Common Stock, Shares Authorized (in shares) | 800,000,000 | 800,000,000 | 800,000,000 |
Common Stock, Shares Issued (in shares) | 237,169,770 | 237,169,770 | 193,044,766 |
Common Stock, Shares Outstanding (in shares) | 236,994,770 | 236,719,770 | 193,044,766 |
Consolidated Statements of Op_2
Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Revenue | $ 6,261 | $ 0 | $ 14,086 | $ 10,000 |
Operating expense: | ||||
Cost of revenues | 17,140 | 0 | 51,363 | 10,102 |
Selling, general and administrative expense | 836,215 | 1,370,395 | 3,308,227 | 3,600,419 |
Research and development expense | 159,846 | 297,553 | 922,120 | 1,051,755 |
Total costs and expenses | 1,013,200 | 1,667,948 | 4,281,710 | 4,662,276 |
Loss from operations | (1,006,940) | (1,667,948) | (4,267,624) | (4,652,276) |
Other income (expense): | ||||
Interest expense | (39,890) | (40,186) | (119,671) | (110,202) |
Gain on forgiveness of loan | 0 | 178,229 | 178,229 | |
Decrease to fair value of derivative liability | 0 | 0 | 1,000,000 | 108,944 |
Total other income (expense) | (39,890) | 138,043 | 880,329 | 176,971 |
Net loss | $ (1,046,830) | $ (1,529,905) | $ (3,387,295) | $ (4,475,305) |
Loss per share - basic and diluted | ||||
Net loss per common share - basic and diluted (in dollars per share) | $ 0 | $ (0.01) | $ (0.01) | $ (0.02) |
Weighted common shares - basic and diluted (in shares) | 236,947,517 | 236,719,770 | 236,853,195 | 214,289,567 |
Consolidated Statements of Ch_2
Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($) | Common Stock Outstanding [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance at Sep. 30, 2019 | $ 37,885,151 | $ (38,865,060) | $ (807,297) | |
Net loss | (4,691,377) | |||
Vesting of restricted stock | (965) | 0 | 0 | |
Stock-based compensation expense | 898,293 | 0 | 898,293 | |
Vesting of restricted stock | (965) | 0 | 0 | |
Balance (in shares) at Sep. 30, 2020 | 193,044,766 | |||
Balance at Sep. 30, 2020 | $ 193,045 | 41,862,901 | (43,556,437) | (1,500,491) |
Net loss | $ 0 | 0 | (4,475,305) | (4,475,305) |
Vesting of restricted stock (in shares) | 550,000 | |||
Vesting of restricted stock | $ 550 | (550) | 0 | 0 |
Stock-based compensation expense | $ 0 | 372,196 | 0 | 372,196 |
Issuance of common stock and warrants, net of financing costs (in shares) | 43,125,004 | |||
Issuance of common stock and warrants, net of financing costs | $ 43,125 | 6,176,108 | 0 | 6,219,233 |
Vesting of restricted stock (in shares) | 550,000 | |||
Vesting of restricted stock | $ 550 | (550) | 0 | 0 |
Balance (in shares) at Jun. 30, 2021 | 236,719,770 | |||
Balance at Jun. 30, 2021 | $ 236,720 | 48,410,655 | (48,031,742) | 615,633 |
Balance (in shares) at Sep. 30, 2020 | 193,044,766 | |||
Balance at Sep. 30, 2020 | $ 193,045 | 41,862,901 | (43,556,437) | (1,500,491) |
Net loss | (6,240,482) | |||
Stock-based compensation expense | 496,066 | 0 | 496,066 | |
Balance (in shares) at Sep. 30, 2021 | 236,719,770 | |||
Balance at Sep. 30, 2021 | $ 236,720 | 48,534,525 | (49,796,919) | (1,025,674) |
Balance (in shares) at Mar. 31, 2021 | 236,719,770 | |||
Balance at Mar. 31, 2021 | $ 236,720 | 48,316,799 | (46,501,837) | 2,051,682 |
Net loss | 0 | 0 | (1,529,905) | (1,529,905) |
Stock-based compensation expense | $ 0 | 93,856 | 0 | 93,856 |
Balance (in shares) at Jun. 30, 2021 | 236,719,770 | |||
Balance at Jun. 30, 2021 | $ 236,720 | 48,410,655 | (48,031,742) | 615,633 |
Balance (in shares) at Sep. 30, 2021 | 236,719,770 | |||
Balance at Sep. 30, 2021 | $ 236,720 | 48,534,525 | (49,796,919) | (1,025,674) |
Net loss | $ 0 | 0 | (3,387,295) | (3,387,295) |
Vesting of restricted stock (in shares) | 275,000 | |||
Vesting of restricted stock | $ 275 | (275) | 0 | 0 |
Stock-based compensation expense | $ 0 | 397,470 | 0 | 397,470 |
Vesting of restricted stock (in shares) | 275,000 | |||
Vesting of restricted stock | $ 275 | (275) | 0 | 0 |
Balance (in shares) at Jun. 30, 2022 | 236,994,770 | |||
Balance at Jun. 30, 2022 | $ 236,995 | 48,931,720 | (53,184,214) | (4,015,499) |
Balance (in shares) at Mar. 31, 2022 | 236,919,770 | |||
Balance at Mar. 31, 2022 | $ 236,920 | 48,841,040 | (52,137,384) | (3,059,424) |
Net loss | $ 0 | 0 | (1,046,830) | (1,046,830) |
Vesting of restricted stock (in shares) | 75,000 | |||
Vesting of restricted stock | $ 75 | (75) | 0 | 0 |
Stock-based compensation expense | $ 0 | 90,755 | 0 | 90,755 |
Vesting of restricted stock (in shares) | 75,000 | |||
Vesting of restricted stock | $ 75 | (75) | 0 | 0 |
Balance (in shares) at Jun. 30, 2022 | 236,994,770 | |||
Balance at Jun. 30, 2022 | $ 236,995 | $ 48,931,720 | $ (53,184,214) | $ (4,015,499) |
Consolidated Statements of Ca_2
Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Sep. 30, 2021 | Sep. 30, 2020 | |
Cash flows from operating activities: | ||||||
Net loss | $ (1,046,830) | $ (1,529,905) | $ (3,387,295) | $ (4,475,305) | $ (6,240,482) | $ (4,691,377) |
Adjustments to reconcile net loss to cash used in operating activities: | ||||||
Depreciation | 799 | 799 | 2,397 | 1,788 | 2,587 | 6,926 |
Stock-based compensation | 397,470 | 372,196 | 496,066 | 898,293 | ||
Decrease to fair value of derivative liability | 0 | 0 | (1,000,000) | (108,944) | ||
Inventory obsolescence charge | 248,073 | 181,988 | 181,988 | 60,385 | ||
Gain on forgiveness of loan | 0 | (178,229) | (178,229) | 0 | ||
Changes in operating assets and liabilities: | ||||||
Inventory | (582,572) | (42,215) | (307,760) | (681,731) | ||
Prepaid expenses and other current assets | 223,854 | (163,135) | (91,668) | 147,032 | ||
Accounts payable | 1,288,130 | (64,853) | 66,033 | (191,505) | ||
Accrued interest | 119,671 | 110,956 | 151,285 | 0 | ||
Accrued expenses and other liabilities | (96,370) | (80,324) | 70,496 | 86,493 | ||
Net cash used in operating activities | (2,786,642) | (4,446,077) | (5,958,628) | (5,044,755) | ||
Cash flows from investing activities: | ||||||
Purchases of property and equipment | 0 | (3,275) | (3,275) | (2,455) | ||
Net cash used in investing activities | 0 | (3,275) | (3,275) | (2,455) | ||
Cash flows from financing activities: | ||||||
Proceeds received from advances from investors | 575,000 | 0 | ||||
Proceeds received from series 2 convertible notes | 0 | 1,050,000 | 1,050,000 | 550,000 | ||
Proceeds from issuance common stock and warrants, net of financing costs | 0 | 6,219,233 | 6,219,233 | 2,167,162 | ||
Net cash provided by financing activities | 575,000 | 7,269,233 | 7,269,233 | 3,826,190 | ||
Net increase (decrease) in cash | (2,211,642) | 2,819,881 | ||||
Cash, beginning of period | 2,266,639 | 959,309 | 959,309 | |||
Cash, end of period | $ 54,977 | $ 3,779,190 | 54,977 | 3,779,190 | 2,266,639 | 959,309 |
Non-cash financing activities: | ||||||
Issuance of restricted stock for services | $ 29,831 | $ 103,750 | $ 103,750 | $ 93,500 |
Note 1 - Description of Busines
Note 1 - Description of Business | 12 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | 1. Arch Therapeutics, Inc., (together with its subsidiary, the “Company” or “Arch”) was incorporated under the laws of the State of Nevada on September 16, 2009, June 26, 2013, ABS was incorporated under the laws of the Commonwealth of Massachusetts on March 6, 2006 April 7, 2008, The Company only recently commenced commercial sales of our first AC5® The Company expects to incur substantial expenses for the foreseeable future relating to research, development and commercialization of its potential products. However, there can be no not |
Note 2 - Summary Of Significant
Note 2 - Summary Of Significant Accounting Policies | 9 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Sep. 30, 2021 | |
Notes to Financial Statements | ||
Significant Accounting Policies [Text Block] | 2. The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“ US GAAP Although the Company believes that the disclosures in these unaudited interim consolidated financial statements are adequate to make the information presented not SEC 10 September 30, 2021, December 17, 2021 ( Annual Report For a complete summary of the Company’s significant accounting policies, please refer to Note 2 8 no nine June 30, 2022. Basis of Presentation The consolidated financial statements include the accounts of Arch Therapeutics, Inc. and its wholly owned subsidiary, Arch Biosurgery, Inc., a biotechnology company. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expense during the reporting periods. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three June 30, 2022 September 30, 2021. Inventories Inventories are stated at the lower of cost or net realizable value. The cost of inventories comprises expenditures incurred in acquiring the inventories, the cost of conversion and other costs incurred in bringing them to their existing location and condition. The cost of raw materials, goods-in-process and finished goods are determined on a First in First out (FiFo) basis. When determining net realizable value, appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may not not Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of the related asset. Upon sale or retirement, the cost and accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in income or loss for the period. Repair and maintenance expenditures are charged to expense as incurred. Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment when circumstances indicate the carrying value of an asset may not FASB ASC 360, Property, Plant and Equipment three nine June 30, 2022 2021 not Leases The Company determines if an arrangement is a lease at its inception. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company’s lease does not Income Taxes In accordance with FASB ASC Topic 740, Income Taxes not not The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions when management determines that it is more likely than not Revenue In accordance with FASB ASC Topic 606, Revenue Recognition five The Company’s source of revenue is product sales. Contracts with customers contain a single performance obligation and the Company recognizes revenue from product sales when the Company has satisfied our performance obligation by transferring control of the product to the customers. Control of the product transfers to the customer upon shipment from the Company’s third Cost of Revenue Cost of revenue includes product costs, warehousing, overhead allocation and royalty expense. Research and Development The Company expenses internal and external research and development costs, including costs of funded research and development arrangements, in the period incurred. Accounting for Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation-Stock Compensation ASC 718 718, Black-Scholes Model The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the fair value of the Common Stock and a number of other assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718 10 S99, no Fair Value Measurements The Company measures both financial and nonfinancial assets and liabilities in accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures three 1 2 1 3 At June 30, 2022 September 30, 2021, 10 Derivative Liabilities The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument, in accordance with FASB ASC Topic 815, Derivatives and Hedging ASC 815 no Going Concern Basis of Accounting As reflected in the consolidated financial statements, the Company has an accumulated deficit, has suffered significant net losses and negative cash flows from operations, only recently commenced generating limited operating revenues, and has limited working capital. The continuation of the Company’s business as a going concern is dependent upon raising additional capital, the ability to successfully market and sell its product(s) and eventually attaining and maintaining profitable operations. As of the date of issuance of the accompanying consolidated financial statements , the Company will be required to raise additional capital, obtain alternative means of financial support, or both, in order to continue to fund operations, and therefore there is substantial doubt about the Company’s ability to continue as a going concern. The Company expects to incur substantial expenses into the foreseeable future for the research, development and commercialization of its current and potential other products. In addition, the Company will require additional financing in order to seek to license or acquire new assets, research and develop any potential patents and the related compounds, and obtain any further intellectual property that the Company may APIs AC5® June 28, 2018 (“ 2018 2018 not 2018 20% 6 2018 The continued spread of coronavirus and geopolitical conflicts, including the recent war in Ukraine, as well as uncertain market conditions, may may The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The consolidated financial statements do not | 2. The accompanying consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“ US GAAP Basis of Presentation The consolidated financial statements include the accounts of Arch Therapeutics, Inc. and its wholly owned subsidiary, Arch Biosurgery, Inc., a biotechnology company. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. Recently Issued and Adopted Accounting Guidance Accounting Standards Update (ASU) 2018 13, 820 August 2018. 820. December 15, 2019. 2018 13 first 2021, ASU 2020 06, 470 02 815 40 August 2020. December 15, 2023. not Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three September 30, 2021 2020. Inventories Inventories are stated at the lower of cost or net realizable value. The cost of inventories comprises expenditures incurred in acquiring the inventories, the cost of conversion and other costs incurred in bringing them to their existing location and condition. The cost of raw materials, goods-in-process and finished goods are determined on a First in First out (FiFo) basis. When determining net realizable value, appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may not not Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of the related asset. Upon sale or retirement, the cost and accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in income or loss for the period. Repair and maintenance expenditures are charged to expense as incurred. Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment when circumstances indicate the carrying value of an asset may not 360, Property, Plant and Equipment September 30, 2021 2020 not Leases The Company determines if an arrangement is a lease at its inception. Operating lease right-of-use (“ROU“) assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As our lease does not September 30, 2021 2020, September 30, 2021 2020, Income Taxes In accordance with FASB ASC 740, Income Taxes not not The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions when management determines that it is more likely than not Revenue In accordance with FASB ASC 606, Revenue Recognition five The Company’s source of revenue is product sales. Contracts with customers contain a single performance obligation and the Company recognizes revenue from product sales when the Company has satisfied our performance obligation by transferring control of the product to the customers. Control of the product transfers to the customer upon shipment from the Company’s third Cost of Revenues Cost of revenues includes product costs, warehousing, overhead allocation and royalty expenses. Research and Development The Company expenses internal and external research and development costs, including costs of funded research and development arrangements, in the period incurred. Accounting for Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation-Stock Compensation 718” 718, The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the fair value of the common stock and a number of other assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718 10 S99 no Fair Value Measurements The Company measures both financial and nonfinancial assets and liabilities in accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures three 1 2 1 3 At September 30, 2021 2020, Derivative Liabilities The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument, in accordance with FASB ASC Topic 815, Derivatives and Hedging no Financial Statement Reclassification Certain balances in the prior year consolidated financial statements have been reclassified for comparison purposes to conform to the presentation in the current period consolidated financial statements. Subsequent Events The Company evaluated all events or transactions through December 16, 2021, no 15 Going Concern Basis of Accounting As reflected in the consolidated financial statements, the Company has an accumulated deficit, has suffered significant net losses and negative cash flows from operations, only recently commenced generating limited operating revenues, and has limited working capital. The continuation of the Company’s business as a going concern is dependent upon raising additional capital, the ability to successfully market and sell its product and eventually attaining and maintaining profitable operations. In particular, as of September 30, 2021, may AC5® February 20, 2017 ( “2017 June 28, 2018 ( “2018 2017 2018 not three 2017 2018 20% 2017 2018 2021 2021 February 11, 2022; may may may The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The consolidated financial statements do not |
Note 3 - Property and Equipment
Note 3 - Property and Equipment | 9 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Sep. 30, 2021 | |
Notes to Financial Statements | ||
Property, Plant and Equipment Disclosure [Text Block] | 3. At June 30, 2022 September 30, 2021, Estimated Useful June 30, September 30, Life (years) 2022 2021 Furniture and fixtures 5 $ 9,357 $ 9,357 Leasehold improvements Life of Lease 8,983 8,983 Computer equipment 3 14,416 14,416 Lab equipment 5 1,000 1,000 33,756 33,756 Less – accumulated depreciation 30,913 28,516 Property and equipment, net $ 2,843 $ 5,240 For the three June 30, 2022 2021, nine June 30, 2022 2021, | 3. At September 30, 2021 2020, Estimated Useful September 30, September 30, Life (years) 2021 2020 Furniture and fixtures 5 $ 9,357 $ 9,357 Leasehold improvements Life of Lease $ 8,983 $ 8,983 Computer equipment 3 $ 14,416 $ 11,141 Lab equipment 5 $ 1,000 $ 1,000 33,756 30,481 Less - accumulated depreciation 28,516 25,929 Property and equipment, net $ 5,240 $ 4,552 For the years ended September 30, 2021 2020 |
Note 4 - Income Taxes
Note 4 - Income Taxes | 12 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 4. The principal components of the Company’s net deferred tax assets consisted of the following at September 30: 2021 2020 Net operating loss carryforwards $ 10,022,020 $ 8,451,214 Capitalized expenditures 1,703,849 1,782,185 Research and experimentation credit carryforwards 946,158 928,734 Stock based compensation 2,352,432 2,321,519 Property and Equipment 2,740 3,152 Accrued expenses 57,812 18,518 Inventory allowance 62,946 16,497 Gross deferred tax assets 15,147,957 13,521,819 Deferred tax asset valuation allowance (15,147,957 ) (13,521,819 Net deferred tax assets $ - $ - The provision (benefit) for income taxes differs from the tax computed with the statutory federal income tax rate as follows: 2021 2020 Expected income tax (benefit) at federal statutory rate 21.00 % 21.00 % Increase/(Decrease) due to: State Taxes - Net of federal benefit 5.80 % 7.08 % Permanent Differences: Key man life insurance (0.01 )% (0.01 )% R&D, taken as a credit (0.29 )% (0.51 )% Adjustment to fair value of derivative 0.37 % 3.04 % PPP Loan Forgiveness 0.60 % 0.00 % Other (1.41 )% 0.51 % Change in Valuation Allowance (26.06 )% (31.11 )% Total Income Tax Provision / Benefit - % - % As of September 30, 2021 2020, may 2018 2026. December 31, 2017 September 30, 2021 2020, September 30, 2021 2020, may 2028. As of September 30, 2021 2020, may 2030. September 30, 2021 2020, may 2023. As the Company has not September 30, 2021 2020 not 740, Income Taxes 2021 2020 The Company experienced an ownership change as a result of the Merger described in Note 1, 382 382 not As of September 30, 2021, September 30, 2021, 2020, 2019 2018. 2010 2020 The Coronavirus Aid, Relief and Economic Security (“CARES”) Act was enacted on March 27, 2020. September 30, 2021 |
Note 5 - Inventories
Note 5 - Inventories | 9 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Sep. 30, 2021 | |
Notes to Financial Statements | ||
Inventory Disclosure [Text Block] | 4 INVENTORIES Inventories consist of the following: June 30, September 30, 2022 2021 Finished goods $ — $ 249,571 Goods-in-process 1,428,264 844,194 Total $ 1,428,264 $ 1,093,765 The Company capitalizes inventory that has been produced for commercial sale and has been determined to have a probable future economic benefit. The determination of whether or not | 5 INVENTORIES Inventories consist of the following: September 30, September 30, 2021 2020 Finished Goods $ 249,571 $ - Goods-in-process 844,194 967,993 Total $ 1,093,765 $ 967,993 The Company capitalizes inventory that has been produced for commercial sale and has been determined to have a probable future economic benefit. The determination of whether or not |
Note 6 - Registered Direct Offe
Note 6 - Registered Direct Offerings | 12 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Stockholders' Equity Note, Direct Offerings [Text Block] | 6. On September 30, 2016, October 20, 2016 ( may On February 24, 2017, “2017 6 “2017 2017 “2017 2017 2017 fifth “2017 2017 “2017 On July 2, 2018, “2018 “2018 2018 “2018 2018 2018 fifth “2018 2018 On May 12, 2019, "2019 "2019 2019 "2019 2019 one fifth 2019 2019 "2019 During the years ended September 30, 2021 2020 September 30, 2021, may |
Note 7 - Derivative Liabilities
Note 7 - Derivative Liabilities | 12 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Derivative Liabilities [Text Block] | 7. The Company accounted for the Series F Warrants relating to the 2017 2018 2019 815 10, Derivatives and Hedging may not On the respective closing dates, the Series F, Series G and Series H derivative liabilities were recorded at an aggregate fair value of $1,628,113. Given that the fair value of the derivative liabilities were less than the net proceeds, the remaining proceeds were allocated to Common Stock and additional-paid-in-capital. During the fiscal years ended September 30, 2021 2020, Fair Value Measurements Using Significant Unobservable Inputs - September 30, 2021 (Level 3) Series F Series G Series H Beginning balance at September 30, 2020 $ 1,000,000 $ 748,275 $ 568,144 Issuances - - - Adjustments to estimated fair value - - (108,944 Ending balance at September 30, 2021 $ 1,000,000 $ 748,275 $ 459,200 Fair Value Measurements Using Significant Unobservable Inputs - September 30, 2020 (Level 3) Series F Series G Series H Beginning balance at September 30, 2019 $ 1,000,000 $ 748,275 $ 1,247,415 Issuances - - - Adjustments to estimated fair value - - (679,271 Ending balance at September 30, 2020 $ 1,000,000 $ 748,275 $ 568,144 The derivative liabilities were valued as of September 30, 2021 Series F Series G Series H Closing price per share of common stock $ 0.12 $ 0.12 $ 0.12 Exercise price per share $ 0.75 $ 0.7 $ 0.4 Expected volatility 90.28 % 87.4 % 86.59 % Risk-free interest rate 0.04 % 0.19 % 0.41 % Dividend yield — — — Remaining expected term of underlying securities (years) 0.34 1.7 2.58 The derivative liabilities were valued as of September 30, 2020 Series F Series G Series H Closing price per share of common stock $ 0.17 $ 0.17 $ 0.17 Exercise price per share $ 0.75 $ 0.7 $ 0.4 Expected volatility 84.17 % 83.31 % 82.24 % Risk-free interest rate 0.13 % 0.15 % 0.22 % Dividend yield — — — Remaining expected term of underlying securities (years) 1.35 2.71 3.6 |
Note 8 - October 2019 Registere
Note 8 - October 2019 Registered Direct Offering | 12 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Stockholders Equity Note Direct Offering 2019 October [Text Block] | 8. OCTOBER 2019 On October 16, 2019, “October 2019 7 “October 2019 2019 “October 2019 October 2019 one fifth “October 2019 October 2019 “October 2019 October 18, 2019, five The gross proceeds to Arch from the October 2019 October 18, 2019, We engaged H.C. Wainwright (“Wainwright”) as our exclusive institutional investor placement agent in connection with the October October 10, 2019, During the year ended September 30, 2021, September 30, 2021, may Common Stock At October 18, 2019 October 2019 Equity Value of Warrants The Company accounted for the Series I Warrants and the Placement Agent Warrants relating to the aforementioned October 2019 815 40, Derivatives and Hedging |
Note 9 - 2021 Registered Direct
Note 9 - 2021 Registered Direct Offering | 12 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Stockholders Equity Note Direct Offering 2021 [Text Block] | 9. 2021 On February 11, 2021, “2021 “2021 2021 “2021 February 8, 2021, 2021 one 2 The Placement Agent 2 2 The 2021 2021 February 11, 2022; may The number of shares of the Company’s Common Stock into which each of the Series K Warrants is exercisable and the exercise price therefore are subject to adjustment, as set forth in the Series K Warrants, including adjustments for stock subdivisions or combinations (by any stock split, stock dividend, recapitalization, reorganization, scheme, arrangement or otherwise). During the the fiscal year ended September 30, 2021, 2 June 30, 2021, may Common Stock On February 17, 2021 2021 Equity Value of Warrants The Company accounted for the Series K Warrants and the Placement Agent 2 February 2021 815 40, Derivatives and Hedging 2 |
Note 10 - Convertible Notes
Note 10 - Convertible Notes | 12 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | 10. On June 4, 2020 November 6, 2020, 1 1” 2 2” 1 2 June 30, 2023 November 30, 2023, 1 2 three 3 1 2 not 1 2 fifteen thirty-five ten twelve ten On June 3, 2020, June 4, 2020, November 6, 2020, one thirty On June 22, 2020, June 22, 2020, During the fiscal years ended September 30, 2021 2020, $18,000,respectively. |
Note 11- Payroll Protection Pro
Note 11- Payroll Protection Program Loan | 12 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Payroll Protection Program Loan [Text Block] | 11. On April 25, 2020, The PPP Loan had a two The PPP Note contains customary events of default relating to, among other things, payment defaults, providing materially false and misleading representations to the SBA or Lender, or breaching the terms of the PPP Loan documents. The occurrence of an event of default may Under the terms of the CARES Act, PPP Loan recipients can apply for and be granted forgiveness for all or a portion of the loan granted under the PPP. Such forgiveness will be determined, subject to limitations, based on the use of loan proceeds for payment of payroll costs and any payments of mortgage interest, rent, and utilities. However, no November 2020, May 28, 2021, September 30, 2021, |
Note 12 - Stock-based Compensat
Note 12 - Stock-based Compensation | 9 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Sep. 30, 2021 | |
Notes to Financial Statements | ||
Share-Based Payment Arrangement [Text Block] | 5. 2013 On June 18, 2013, 2013 2013 2013 September 30, 2021, options Restricted Stock may one two 2013 first 2014, 2013 3,000,000 four Board October 1, 2021, 2013Plan The exercise price of each option is equal to the closing price of a share of the Company’s Common Stock on the date of grant. Share-Based Awards During the nine June 30, 2022, 2013 . Share-based compensation expense for awards granted during the nine June 30, 2022 Common Stock Options Stock compensation activity under the 2013 nine June 30, 2022 Option Shares Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at September 30, 2021 24,899,014 $ 0.29 1.83 $ 140,151 Awarded 675,000 0.06 — — Forfeited/Cancelled (3,083,818 ) 0.33 — — Outstanding at June 30, 2022 22,490,196 0.28 1.47 — Vested at June 30, 2022 19,135,976 0.31 1.70 — Vested and expected to vest at June 30, 2022 22,490,196 0.28 1.47 — As of June 30, 2022, 2013 Share-based compensation expense recorded in the Company’s Consolidated Statements of Operations for the three June 30, 2022 2021 three June 30, 2022 2021, Share-based compensation expense recorded in the Company’s Consolidated Statements of Operations for the nine June 30, 2022 2021 nine June 30, 2022 2021, nine June 30, 2022 2021, As of June 30, 2022, 2013 Restricted Stock Restricted Stock activity under the 2013 nine June 30, 2022 2021, Nine Months Ended June 30, 2022 June 30, 2021 Non Vested at September 30, 2021 and 2020 450,000 — Awarded — 550,000 Vested (275,000 ) (550,000 ) Forfeited — — Non Vested at June 30, 2022 and 2021 175,000 — The weighted average Restricted Stock award date fair value information for the nine June 30, 2022 2021 Nine Months Ended June 30, 2022 June 30, 2021 Non Vested at September 30, 2021 and 2020 $ 0.10 $ — Awarded — 0.19 Vested (0.10 ) (0.19 ) Forfeited — — Non Vested at June 30, 2022 and 2021 $ 0.10 $ — For the three June 30, 2022 2021, nine June 30, 2022 2021, | 12. 2013 On June 18, 2013, 2013 “2013 2013 September 30, 2021, may one two 2013 first 2014, 2013 four 4 October 1, 2020, As of September 30, 2021, Share-based awards During the year ended September 30, 2021, 2013 . Share-based compensation expense for awards granted during the year ended September 30, 2021 September 30, 2021; Common Stock Options Stock compensation activity under the 2013 September 30, 2021 Weighted Average Weighted Option Average Remaining Aggregate Shares Exercise Contractual Intrinsic Outstanding Price Term (years) Value Outstanding at September 30, 2020 18,248,346 $ 0.36 2.59 $ 79,330 Awarded 7,375,000 $ 0.12 - - Forfeited/Cancelled (724,332 ) $ 0.44 - - Outstanding at September 30, 2021 24,899,014 $ 0.29 1.83 $ 140,151 Vested at September 30, 2021 18,814,908 $ 0.35 2.17 $ 17,122 Vested and expected to vest at September 30, 2021 24,899,014 $ 0.29 1.83 $ 140,151 As of September 30, 2021, 2013 September 30, 2021 2020 September 30, 2021 2020, During the years ended September 30, 2021 2020, 2013 September 30, 2021 2020, 2013 As of September 30, 2021, 2013 Restricted Stock On October 14, 2020, 2013 January 27, 2021, 2013 July 30, 2021, 2013 January 12, 2022, July 12, 2022 January 12, 2023. September 27, 2021, 2013 1/12 twelve On July 19, 2018, 2013 second 2013 September 30, 2021, Restricted stock activity in shares under the 2013 September 30, 2021 2020 2021 2020 Non Vested at September 30, 2020 and 2019 - 965,000 Awarded 1,000,000 - Vested (550,000 ) (965,000 ) Forfeited - - Non Vested at September 30, 2021 and 2020 450,000 - The weighted average restricted stock award date fair value information for the years ended September 30, 2021 2019 2021 2020 Non Vested at September 30, 2020 and 2019 $ - $ 0.43 Awarded 0.13 - Vested (0.16 ) (0.43 ) Forfeited - - Non Vested at September 30, 2021 and 2020 $ 0.10 $ - For the years ended September 30, 2021 2020 September 30, 2021, 2013 |
Note 13 - Commitments and Conti
Note 13 - Commitments and Contingencies | 12 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 13. In the ordinary course of business, the Company enters into various agreements containing standard indemnification provisions. The Company’s indemnification obligations under such provisions are typically in effect from the date of execution of the applicable agreement through the end of the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. As of September 30, 2021 2020, no From time to time, the Company may MIT Licensing Agreement In December 2007, not In exchange for the licenses granted in the agreement, the Company has paid MIT license maintenance fees and patent prosecution costs. The Company paid license maintenance fees of $50,000 to MIT in the fiscal years ended September 30, 2021 2020. September 30, 2021 2020, January 1 December 31. may The Company is obligated to indemnify MIT and related parties from losses arising from claims relating to the exercise of any rights granted to the Company under the license, with certain exceptions. The maximum potential amount of future payments the Company could be required to make under this provision is unlimited. The Company considers there to be a low performance risk as of September 30, 2021. The agreement expires upon the expiration or abandonment of all patents that are issued and licensed to the Company by MIT under such agreement. The Company expects that patents will be issued from presently pending U.S. and foreign patent applications. Any such patent will have a term of 20 years from the filing date of the underlying application. MIT may not not may six Leases The Company's corporate offices are located in Framingham, MA. During July 2017, three October 1, 2017 September 30, 2020 first second third August 2020, September 30, 2021 $42,000. October 2021 six March 31, 2022 September 30, 2021 2020, $0 $39,000, |
Note 14 - Risks and Uncertainti
Note 14 - Risks and Uncertainties - COVID-19 | 12 Months Ended |
Sep. 30, 2021 | |
Notes to Financial Statements | |
Unusual or Infrequent Items, or Both, Disclosure [Text Block] | 14. 19 The Company sources its materials and services for its products and product candidates from facilities in areas impacted or which may may may |
Note 1 - Basis of Presentation
Note 1 - Basis of Presentation and Description of Business | 9 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
Business Description and Basis of Presentation [Text Block] | 1. Arch Therapeutics, Inc. (together with its subsidiary, the “ Company Arch September 16, 2009, June 26, 2013, Merger ABS Merger Sub ABS was incorporated under the laws of the Commonwealth of Massachusetts on March 6, 2006, April 7, 2008, In the first 2021, first AC5® Common Stock warrants The Company expects to incur substantial expenses for the foreseeable future relating to research, development and commercialization of its potential products. However, there can be no not |
Note 2 - Summary of Significa_2
Note 2 - Summary of Significant Accounting Policies | 9 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Sep. 30, 2021 | |
Notes to Financial Statements | ||
Significant Accounting Policies [Text Block] | 2. The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“ US GAAP Although the Company believes that the disclosures in these unaudited interim consolidated financial statements are adequate to make the information presented not SEC 10 September 30, 2021, December 17, 2021 ( Annual Report For a complete summary of the Company’s significant accounting policies, please refer to Note 2 8 no nine June 30, 2022. Basis of Presentation The consolidated financial statements include the accounts of Arch Therapeutics, Inc. and its wholly owned subsidiary, Arch Biosurgery, Inc., a biotechnology company. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expense during the reporting periods. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three June 30, 2022 September 30, 2021. Inventories Inventories are stated at the lower of cost or net realizable value. The cost of inventories comprises expenditures incurred in acquiring the inventories, the cost of conversion and other costs incurred in bringing them to their existing location and condition. The cost of raw materials, goods-in-process and finished goods are determined on a First in First out (FiFo) basis. When determining net realizable value, appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may not not Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of the related asset. Upon sale or retirement, the cost and accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in income or loss for the period. Repair and maintenance expenditures are charged to expense as incurred. Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment when circumstances indicate the carrying value of an asset may not FASB ASC 360, Property, Plant and Equipment three nine June 30, 2022 2021 not Leases The Company determines if an arrangement is a lease at its inception. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company’s lease does not Income Taxes In accordance with FASB ASC Topic 740, Income Taxes not not The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions when management determines that it is more likely than not Revenue In accordance with FASB ASC Topic 606, Revenue Recognition five The Company’s source of revenue is product sales. Contracts with customers contain a single performance obligation and the Company recognizes revenue from product sales when the Company has satisfied our performance obligation by transferring control of the product to the customers. Control of the product transfers to the customer upon shipment from the Company’s third Cost of Revenue Cost of revenue includes product costs, warehousing, overhead allocation and royalty expense. Research and Development The Company expenses internal and external research and development costs, including costs of funded research and development arrangements, in the period incurred. Accounting for Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation-Stock Compensation ASC 718 718, Black-Scholes Model The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the fair value of the Common Stock and a number of other assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718 10 S99, no Fair Value Measurements The Company measures both financial and nonfinancial assets and liabilities in accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures three 1 2 1 3 At June 30, 2022 September 30, 2021, 10 Derivative Liabilities The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument, in accordance with FASB ASC Topic 815, Derivatives and Hedging ASC 815 no Going Concern Basis of Accounting As reflected in the consolidated financial statements, the Company has an accumulated deficit, has suffered significant net losses and negative cash flows from operations, only recently commenced generating limited operating revenues, and has limited working capital. The continuation of the Company’s business as a going concern is dependent upon raising additional capital, the ability to successfully market and sell its product(s) and eventually attaining and maintaining profitable operations. As of the date of issuance of the accompanying consolidated financial statements , the Company will be required to raise additional capital, obtain alternative means of financial support, or both, in order to continue to fund operations, and therefore there is substantial doubt about the Company’s ability to continue as a going concern. The Company expects to incur substantial expenses into the foreseeable future for the research, development and commercialization of its current and potential other products. In addition, the Company will require additional financing in order to seek to license or acquire new assets, research and develop any potential patents and the related compounds, and obtain any further intellectual property that the Company may APIs AC5® June 28, 2018 (“ 2018 2018 not 2018 20% 6 2018 The continued spread of coronavirus and geopolitical conflicts, including the recent war in Ukraine, as well as uncertain market conditions, may may The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The consolidated financial statements do not | 2. The accompanying consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“ US GAAP Basis of Presentation The consolidated financial statements include the accounts of Arch Therapeutics, Inc. and its wholly owned subsidiary, Arch Biosurgery, Inc., a biotechnology company. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. Recently Issued and Adopted Accounting Guidance Accounting Standards Update (ASU) 2018 13, 820 August 2018. 820. December 15, 2019. 2018 13 first 2021, ASU 2020 06, 470 02 815 40 August 2020. December 15, 2023. not Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three September 30, 2021 2020. Inventories Inventories are stated at the lower of cost or net realizable value. The cost of inventories comprises expenditures incurred in acquiring the inventories, the cost of conversion and other costs incurred in bringing them to their existing location and condition. The cost of raw materials, goods-in-process and finished goods are determined on a First in First out (FiFo) basis. When determining net realizable value, appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may not not Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of the related asset. Upon sale or retirement, the cost and accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in income or loss for the period. Repair and maintenance expenditures are charged to expense as incurred. Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment when circumstances indicate the carrying value of an asset may not 360, Property, Plant and Equipment September 30, 2021 2020 not Leases The Company determines if an arrangement is a lease at its inception. Operating lease right-of-use (“ROU“) assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As our lease does not September 30, 2021 2020, September 30, 2021 2020, Income Taxes In accordance with FASB ASC 740, Income Taxes not not The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions when management determines that it is more likely than not Revenue In accordance with FASB ASC 606, Revenue Recognition five The Company’s source of revenue is product sales. Contracts with customers contain a single performance obligation and the Company recognizes revenue from product sales when the Company has satisfied our performance obligation by transferring control of the product to the customers. Control of the product transfers to the customer upon shipment from the Company’s third Cost of Revenues Cost of revenues includes product costs, warehousing, overhead allocation and royalty expenses. Research and Development The Company expenses internal and external research and development costs, including costs of funded research and development arrangements, in the period incurred. Accounting for Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation-Stock Compensation 718” 718, The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the fair value of the common stock and a number of other assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718 10 S99 no Fair Value Measurements The Company measures both financial and nonfinancial assets and liabilities in accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures three 1 2 1 3 At September 30, 2021 2020, Derivative Liabilities The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument, in accordance with FASB ASC Topic 815, Derivatives and Hedging no Financial Statement Reclassification Certain balances in the prior year consolidated financial statements have been reclassified for comparison purposes to conform to the presentation in the current period consolidated financial statements. Subsequent Events The Company evaluated all events or transactions through December 16, 2021, no 15 Going Concern Basis of Accounting As reflected in the consolidated financial statements, the Company has an accumulated deficit, has suffered significant net losses and negative cash flows from operations, only recently commenced generating limited operating revenues, and has limited working capital. The continuation of the Company’s business as a going concern is dependent upon raising additional capital, the ability to successfully market and sell its product and eventually attaining and maintaining profitable operations. In particular, as of September 30, 2021, may AC5® February 20, 2017 ( “2017 June 28, 2018 ( “2018 2017 2018 not three 2017 2018 20% 2017 2018 2021 2021 February 11, 2022; may may may The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The consolidated financial statements do not |
Note 3 - Property and Equipme_2
Note 3 - Property and Equipment (10Q) | 9 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Sep. 30, 2021 | |
Notes to Financial Statements | ||
Property, Plant and Equipment Disclosure [Text Block] | 3. At June 30, 2022 September 30, 2021, Estimated Useful June 30, September 30, Life (years) 2022 2021 Furniture and fixtures 5 $ 9,357 $ 9,357 Leasehold improvements Life of Lease 8,983 8,983 Computer equipment 3 14,416 14,416 Lab equipment 5 1,000 1,000 33,756 33,756 Less – accumulated depreciation 30,913 28,516 Property and equipment, net $ 2,843 $ 5,240 For the three June 30, 2022 2021, nine June 30, 2022 2021, | 3. At September 30, 2021 2020, Estimated Useful September 30, September 30, Life (years) 2021 2020 Furniture and fixtures 5 $ 9,357 $ 9,357 Leasehold improvements Life of Lease $ 8,983 $ 8,983 Computer equipment 3 $ 14,416 $ 11,141 Lab equipment 5 $ 1,000 $ 1,000 33,756 30,481 Less - accumulated depreciation 28,516 25,929 Property and equipment, net $ 5,240 $ 4,552 For the years ended September 30, 2021 2020 |
Note 4 - Inventories
Note 4 - Inventories | 9 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Sep. 30, 2021 | |
Notes to Financial Statements | ||
Inventory Disclosure [Text Block] | 4 INVENTORIES Inventories consist of the following: June 30, September 30, 2022 2021 Finished goods $ — $ 249,571 Goods-in-process 1,428,264 844,194 Total $ 1,428,264 $ 1,093,765 The Company capitalizes inventory that has been produced for commercial sale and has been determined to have a probable future economic benefit. The determination of whether or not | 5 INVENTORIES Inventories consist of the following: September 30, September 30, 2021 2020 Finished Goods $ 249,571 $ - Goods-in-process 844,194 967,993 Total $ 1,093,765 $ 967,993 The Company capitalizes inventory that has been produced for commercial sale and has been determined to have a probable future economic benefit. The determination of whether or not |
Note 5 - Stock-based Compensati
Note 5 - Stock-based Compensation | 9 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Sep. 30, 2021 | |
Notes to Financial Statements | ||
Share-Based Payment Arrangement [Text Block] | 5. 2013 On June 18, 2013, 2013 2013 2013 September 30, 2021, options Restricted Stock may one two 2013 first 2014, 2013 3,000,000 four Board October 1, 2021, 2013Plan The exercise price of each option is equal to the closing price of a share of the Company’s Common Stock on the date of grant. Share-Based Awards During the nine June 30, 2022, 2013 . Share-based compensation expense for awards granted during the nine June 30, 2022 Common Stock Options Stock compensation activity under the 2013 nine June 30, 2022 Option Shares Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at September 30, 2021 24,899,014 $ 0.29 1.83 $ 140,151 Awarded 675,000 0.06 — — Forfeited/Cancelled (3,083,818 ) 0.33 — — Outstanding at June 30, 2022 22,490,196 0.28 1.47 — Vested at June 30, 2022 19,135,976 0.31 1.70 — Vested and expected to vest at June 30, 2022 22,490,196 0.28 1.47 — As of June 30, 2022, 2013 Share-based compensation expense recorded in the Company’s Consolidated Statements of Operations for the three June 30, 2022 2021 three June 30, 2022 2021, Share-based compensation expense recorded in the Company’s Consolidated Statements of Operations for the nine June 30, 2022 2021 nine June 30, 2022 2021, nine June 30, 2022 2021, As of June 30, 2022, 2013 Restricted Stock Restricted Stock activity under the 2013 nine June 30, 2022 2021, Nine Months Ended June 30, 2022 June 30, 2021 Non Vested at September 30, 2021 and 2020 450,000 — Awarded — 550,000 Vested (275,000 ) (550,000 ) Forfeited — — Non Vested at June 30, 2022 and 2021 175,000 — The weighted average Restricted Stock award date fair value information for the nine June 30, 2022 2021 Nine Months Ended June 30, 2022 June 30, 2021 Non Vested at September 30, 2021 and 2020 $ 0.10 $ — Awarded — 0.19 Vested (0.10 ) (0.19 ) Forfeited — — Non Vested at June 30, 2022 and 2021 $ 0.10 $ — For the three June 30, 2022 2021, nine June 30, 2022 2021, | 12. 2013 On June 18, 2013, 2013 “2013 2013 September 30, 2021, may one two 2013 first 2014, 2013 four 4 October 1, 2020, As of September 30, 2021, Share-based awards During the year ended September 30, 2021, 2013 . Share-based compensation expense for awards granted during the year ended September 30, 2021 September 30, 2021; Common Stock Options Stock compensation activity under the 2013 September 30, 2021 Weighted Average Weighted Option Average Remaining Aggregate Shares Exercise Contractual Intrinsic Outstanding Price Term (years) Value Outstanding at September 30, 2020 18,248,346 $ 0.36 2.59 $ 79,330 Awarded 7,375,000 $ 0.12 - - Forfeited/Cancelled (724,332 ) $ 0.44 - - Outstanding at September 30, 2021 24,899,014 $ 0.29 1.83 $ 140,151 Vested at September 30, 2021 18,814,908 $ 0.35 2.17 $ 17,122 Vested and expected to vest at September 30, 2021 24,899,014 $ 0.29 1.83 $ 140,151 As of September 30, 2021, 2013 September 30, 2021 2020 September 30, 2021 2020, During the years ended September 30, 2021 2020, 2013 September 30, 2021 2020, 2013 As of September 30, 2021, 2013 Restricted Stock On October 14, 2020, 2013 January 27, 2021, 2013 July 30, 2021, 2013 January 12, 2022, July 12, 2022 January 12, 2023. September 27, 2021, 2013 1/12 twelve On July 19, 2018, 2013 second 2013 September 30, 2021, Restricted stock activity in shares under the 2013 September 30, 2021 2020 2021 2020 Non Vested at September 30, 2020 and 2019 - 965,000 Awarded 1,000,000 - Vested (550,000 ) (965,000 ) Forfeited - - Non Vested at September 30, 2021 and 2020 450,000 - The weighted average restricted stock award date fair value information for the years ended September 30, 2021 2019 2021 2020 Non Vested at September 30, 2020 and 2019 $ - $ 0.43 Awarded 0.13 - Vested (0.16 ) (0.43 ) Forfeited - - Non Vested at September 30, 2021 and 2020 $ 0.10 $ - For the years ended September 30, 2021 2020 September 30, 2021, 2013 |
Note 6 - Registered Direct Of_2
Note 6 - Registered Direct Offerings That Created Derivative Liabilities | 9 Months Ended |
Jun. 30, 2022 | |
Registered Direct Offerings [Member] | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | 6. On September 30, 2016, October 20, 2016 Shelf Registration Statement may On February 20, 2017, 2017 six 2017 2017 2017 2017 Series F Warrant fifth 2017 2017 2017 On June 28, 2018, 2018 eight 2018 2018 2018 2018 Series G Warrant fifth 2018 2018 2018 On May 12, 2019, 2019 five 2019 2019 2019 2019 one Series H Warrant fifth 2019 2019 2019 During the three nine June 30, 2022 2021, June 30, 2022, 6,802,500 may June 30, 2022, may three nine June 30, 2022, |
Note 7 - Derivative Liabiliti_2
Note 7 - Derivative Liabilities (10Q) | 9 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
Derivatives and Fair Value [Text Block] | 7. The Company accounted for the Series F Warrants, the Series G Warrants and the Series H Warrants in accordance with ASC 815 10. may Minimum not On the respective closing dates, the derivative liabilities related to the Series F Warrants, Series G Warrants and Series H Warrants were recorded at an aggregate fair value of $1,628,113. Given that the fair value of the derivative liabilities was less than the net proceeds, the remaining proceeds were allocated to Common Stock and additional-paid-in-capital. During the three June 30, 2022 2021, nine June 30, 2022 2021, Fair Value Measurements Using Significant Unobservable Inputs - Nine Months Ended June 30, 2022 (Level 3) Series F Series G Series H Beginning balance at September 30, 2021 $ 1,000,000 $ 748,275 $ 459,200 Issuances — — — Adjustments to estimated fair value (1,000,000 ) — — Ending balance at June 30, 2022 $ — $ 748,275 $ 459,200 Fair Value Measurements Using Significant Unobservable Inputs Year Ended September 30, 2021 (Level 3) Series F Series G Series H Beginning balance at September 30, 2020 $ 1,000,000 $ 748,275 $ 568,144 Issuances — — — Adjustments to estimated fair value — — (108,944 ) Ending balance at September 30, 2021 $ 1,000,000 $ 748,275 $ 459,200 The derivative liabilities were valued as of June 30, 2022 Series G Series H Closing price per share of Common Stock $ 0.046 $ 0.046 Exercise price per share $ 0.70 $ 0.40 Expected volatility 106.18 % 95.85 % Risk-free interest rate 2.80 % 2.92 % Dividend yield — — Remaining expected term of underlying securities (years) 0.94 1.83 The derivative liabilities were valued as of September 30, 2021 Series F Series G Series H Closing price per share of Common Stock $ 0.12 $ 0.12 $ 0.12 Exercise price per share $ 0.75 $ 0.70 $ 0.40 Expected volatility 90.28 % 87.40 % 86.59 % Risk-free interest rate 0.04 % 0.19 % 0.41 % Dividend yield — — — Remaining expected term of underlying securities (years) 0.34 1.70 2.58 |
Note 8 - October 2019 Registe_2
Note 8 - October 2019 Registered Direct Offering | 9 Months Ended |
Jun. 30, 2022 | |
October 2019 Registered Direct Offering [Member] | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | 8. OCTOBER 2019 On October 16, 2019, October 2019 seven October 2019 2019 October 2019 Financing October 2019 Series I Warrant fifth October 2019 Shares October 18, 2019, 14,285,714 Placement Agent Warrants five The gross proceeds to the Company from the October 2019 October 18, 2019, The Company engaged H.C. Wainwright as its exclusive institutional investor placement agent (the “ Placement Agent October 2019 October 10, 2019 ( 2019 $2.5 $158,000. During the nine June 30, 2022 2021, June 30, 2022, may Common Stock On October 18, 2019, October 2019 14,285,714 Equity Value of Warrants The Company accounted for the Series I Warrants and the Placement Agent Warrants relating to the aforementioned October 2019 815 40. |
Note 9 - 2021 Registered Dire_2
Note 9 - 2021 Registered Direct Offering | 9 Months Ended |
Jun. 30, 2022 | |
The 2021 Registered Direct Offering [Member] | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | 9. 2021 On February 11, 2021, 2021 2021 2021 Shares Series K Warrants Warrant Shares 2021 February 8, 2021 ( 2021 2021 one 2021 2021 Placement Agent 2 2 2 2021 The 2021 2021 February 11, 2022; provided, however, may The number of shares of the Company’s Common Stock into which each of the Series K Warrants is exercisable and the exercise price therefore are subject to adjustment, as set forth in the Series K Warrants, including adjustments for stock subdivisions or combinations (by any stock split, stock dividend, recapitalization, reorganization, scheme, arrangement or otherwise). During the nine June 30, 2022, 2 June 30, 2022, may Common Stock On February 17, 2021, 2021 43,125,004 Equity Value of Warrants The Company accounted for the Series K Warrants and the Placement Agent 2 February 2021 815 40, Derivatives and Hedging 2 |
Note 10 - Series 1 and Series 2
Note 10 - Series 1 and Series 2 Convertible Notes | 9 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Sep. 30, 2021 | |
Notes to Financial Statements | ||
Debt Disclosure [Text Block] | 10. On June 4, 2020 November 6, 2020, 1 1” 2 2” 1 2 June 30, 2023 November 30, 2023, 1 2 three 3 1 2 not 1 2 fifteen thirty-five ten twelve ten On June 3, 2020, June 4, 2020, November 6, 2020, one thirty On June 22, 2020, June 22, 2020, During the fiscal years ended September 30, 2021 2020, $18,000,respectively. | |
Series 1 & 2 Convertible Notes [Member] | ||
Notes to Financial Statements | ||
Debt Disclosure [Text Block] | 10. 1 2 On June 4, 2020 November 6, 2020, 1 Series 1 2 Series 2 1 Convertible Notes 1 2 June 30, 2023 November 30, 2023, three not Conversion Price 1 2 Holder VWAP fifteen In-Kind Note Repayment provided, however, thirty-five ten twelve ten March 31, 2022, thirty-five sixty On June 3, 2020, Agreement Majority Holder s Series D Warrants June 4, 2020, 1 Series J Warrants November 6, 2020, one thirty On June 22, 2020, Keyes Sulat Agreement Trust June 22, 2020, one During the three June 30, 2022 2021, nine June 30, 2022 2021, |
Note 11 - Advances from Investo
Note 11 - Advances from Investors | 9 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
Senior Secured Convertible Notes, Warrants and Common Stock, Prefunding [Text Block] | 11. As of June 30, 2022, 14 Terrence Norchi, the Company’s President and Chief Executive Officer, Michael Abrams, the Company’s Chief Financial Officer, and Laurence Hicks, a member of the Company’s board of directors, through Drake Partners LLC, participated in the Convertible Notes Offering for an aggregate of $80,000. |
Note 12 - Payroll Protection Pr
Note 12 - Payroll Protection Program Loan | 9 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Sep. 30, 2021 | |
Notes to Financial Statements | ||
Debt Disclosure [Text Block] | 10. On June 4, 2020 November 6, 2020, 1 1” 2 2” 1 2 June 30, 2023 November 30, 2023, 1 2 three 3 1 2 not 1 2 fifteen thirty-five ten twelve ten On June 3, 2020, June 4, 2020, November 6, 2020, one thirty On June 22, 2020, June 22, 2020, During the fiscal years ended September 30, 2021 2020, $18,000,respectively. | |
Paycheck Protection Program Loan [Member] | ||
Notes to Financial Statements | ||
Debt Disclosure [Text Block] | 12. On April 25, 2020, PPP Note PPP Loan PPP CARES Act SBA Lender The PPP Loan had a two 1.00% not $20,000 The PPP Note contained customary events of default relating to, among other things, payment defaults, providing materially false and misleading representations to the SBA or Lender, or breaching the terms of the PPP Loan documents. The occurrence of an event of default would have resulted in the immediate repayment of all amounts outstanding, collection of all amounts owing from the Company, or filing suit and obtaining judgment. Under the terms of the CARES Act, PPP Loan recipients can apply for and be granted forgiveness for all or a portion of the loan granted under the PPP. Such forgiveness will be determined, subject to limitations, based on the use of loan proceeds for payment of payroll costs and any payments of mortgage interest, rent, and utilities. During November 2020, May 28, 2021, The SBA reserves the right to audit any PPP loan, regardless of size. These audits may six |
Note 13 - Risks and Uncertainti
Note 13 - Risks and Uncertainties - COVID-19 and Geopolitical Conflicts | 9 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
COVID-19 Disclsoure [Text Block] | 13. COVID- 19 The Company sources its materials and services for its products and product candidates from facilities in areas impacted or which may may may |
Note 14 - Subsequent Events
Note 14 - Subsequent Events | 9 Months Ended |
Jun. 30, 2022 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 14. SUBSEQUENT EVENTS The Company evaluated all events or transactions through August 11, 2022, no On July 7, 2022, SPA Investors 2022 2022 2022 2022 Warrant Shares Inducement Shares 2022 2022 2022 Convertible Notes Offering 2022 2022 11 July 6, 2022 ( Closing Date The Company retained a placement agent in connection with the private placement of $2.4 million of the 2022 In addition, as a part of the Convertible Notes Offering, certain holders (the “ Series Holders 1 2 Series Notes 2022 Exchanged Notes 2022 Further, in connection with the 2022 February 15, 2023 2022 2022 2022 2022 2022 |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 9 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Sep. 30, 2021 | |
Accounting Policies [Abstract] | ||
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation The consolidated financial statements include the accounts of Arch Therapeutics, Inc. and its wholly owned subsidiary, Arch Biosurgery, Inc., a biotechnology company. All intercompany accounts and transactions have been eliminated in consolidation. | Basis of Presentation The consolidated financial statements include the accounts of Arch Therapeutics, Inc. and its wholly owned subsidiary, Arch Biosurgery, Inc., a biotechnology company. All intercompany accounts and transactions have been eliminated in consolidation. |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expense during the reporting periods. Actual results could differ from those estimates. | Use of Estimates Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. |
New Accounting Pronouncements, Policy [Policy Text Block] | Recently Issued and Adopted Accounting Guidance Accounting Standards Update (ASU) 2018 13, 820 August 2018. 820. December 15, 2019. 2018 13 first 2021, ASU 2020 06, 470 02 815 40 August 2020. December 15, 2023. not | |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three June 30, 2022 September 30, 2021. | Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three September 30, 2021 2020. |
Inventory, Policy [Policy Text Block] | Inventories Inventories are stated at the lower of cost or net realizable value. The cost of inventories comprises expenditures incurred in acquiring the inventories, the cost of conversion and other costs incurred in bringing them to their existing location and condition. The cost of raw materials, goods-in-process and finished goods are determined on a First in First out (FiFo) basis. When determining net realizable value, appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors. | Inventories Inventories are stated at the lower of cost or net realizable value. The cost of inventories comprises expenditures incurred in acquiring the inventories, the cost of conversion and other costs incurred in bringing them to their existing location and condition. The cost of raw materials, goods-in-process and finished goods are determined on a First in First out (FiFo) basis. When determining net realizable value, appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors. |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may not not | Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may not not |
Property, Plant and Equipment, Policy [Policy Text Block] | Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of the related asset. Upon sale or retirement, the cost and accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in income or loss for the period. Repair and maintenance expenditures are charged to expense as incurred. | Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of the related asset. Upon sale or retirement, the cost and accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in income or loss for the period. Repair and maintenance expenditures are charged to expense as incurred. |
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] | Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment when circumstances indicate the carrying value of an asset may not FASB ASC 360, Property, Plant and Equipment three nine June 30, 2022 2021 not | Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment when circumstances indicate the carrying value of an asset may not 360, Property, Plant and Equipment September 30, 2021 2020 not |
Lessee, Leases [Policy Text Block] | Leases The Company determines if an arrangement is a lease at its inception. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company’s lease does not | Leases The Company determines if an arrangement is a lease at its inception. Operating lease right-of-use (“ROU“) assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As our lease does not September 30, 2021 2020, September 30, 2021 2020, |
Income Tax, Policy [Policy Text Block] | Income Taxes In accordance with FASB ASC Topic 740, Income Taxes not not The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions when management determines that it is more likely than not | Income Taxes In accordance with FASB ASC 740, Income Taxes not not The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions when management determines that it is more likely than not |
Revenue from Contract with Customer [Policy Text Block] | Revenue In accordance with FASB ASC Topic 606, Revenue Recognition five The Company’s source of revenue is product sales. Contracts with customers contain a single performance obligation and the Company recognizes revenue from product sales when the Company has satisfied our performance obligation by transferring control of the product to the customers. Control of the product transfers to the customer upon shipment from the Company’s third | Revenue In accordance with FASB ASC 606, Revenue Recognition five The Company’s source of revenue is product sales. Contracts with customers contain a single performance obligation and the Company recognizes revenue from product sales when the Company has satisfied our performance obligation by transferring control of the product to the customers. Control of the product transfers to the customer upon shipment from the Company’s third |
Cost of Goods and Service [Policy Text Block] | Cost of Revenue Cost of revenue includes product costs, warehousing, overhead allocation and royalty expense. | Cost of Revenues Cost of revenues includes product costs, warehousing, overhead allocation and royalty expenses. |
Research and Development Expense, Policy [Policy Text Block] | Research and Development The Company expenses internal and external research and development costs, including costs of funded research and development arrangements, in the period incurred. | Research and Development The Company expenses internal and external research and development costs, including costs of funded research and development arrangements, in the period incurred. |
Share-Based Payment Arrangement [Policy Text Block] | Accounting for Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation-Stock Compensation ASC 718 718, Black-Scholes Model The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the fair value of the Common Stock and a number of other assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718 10 S99, no | Accounting for Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation-Stock Compensation 718” 718, The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the fair value of the common stock and a number of other assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718 10 S99 no |
Fair Value Measurement, Policy [Policy Text Block] | Fair Value Measurements The Company measures both financial and nonfinancial assets and liabilities in accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures three 1 2 1 3 At June 30, 2022 September 30, 2021, 10 | Fair Value Measurements The Company measures both financial and nonfinancial assets and liabilities in accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures three 1 2 1 3 At September 30, 2021 2020, |
Derivatives, Reporting of Derivative Activity [Policy Text Block] | Derivative Liabilities The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument, in accordance with FASB ASC Topic 815, Derivatives and Hedging no | |
Financial Statement Reclassification [Policy Text Block] | Financial Statement Reclassification Certain balances in the prior year consolidated financial statements have been reclassified for comparison purposes to conform to the presentation in the current period consolidated financial statements. | |
Subsequent Events, Policy [Policy Text Block] | Subsequent Events The Company evaluated all events or transactions through December 16, 2021, no 15 | |
Going Concern Basis Of Accounting [Policy Text Block] | Going Concern Basis of Accounting As reflected in the consolidated financial statements, the Company has an accumulated deficit, has suffered significant net losses and negative cash flows from operations, only recently commenced generating limited operating revenues, and has limited working capital. The continuation of the Company’s business as a going concern is dependent upon raising additional capital, the ability to successfully market and sell its product and eventually attaining and maintaining profitable operations. In particular, as of September 30, 2021, may AC5® February 20, 2017 ( “2017 June 28, 2018 ( “2018 2017 2018 not three 2017 2018 20% 2017 2018 2021 2021 February 11, 2022; may may may The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The consolidated financial statements do not | |
Derivatives, Policy [Policy Text Block] | Derivative Liabilities The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument, in accordance with FASB ASC Topic 815, Derivatives and Hedging ASC 815 no | |
Going Concern [Policy Text Block] | Going Concern Basis of Accounting As reflected in the consolidated financial statements, the Company has an accumulated deficit, has suffered significant net losses and negative cash flows from operations, only recently commenced generating limited operating revenues, and has limited working capital. The continuation of the Company’s business as a going concern is dependent upon raising additional capital, the ability to successfully market and sell its product(s) and eventually attaining and maintaining profitable operations. As of the date of issuance of the accompanying consolidated financial statements , the Company will be required to raise additional capital, obtain alternative means of financial support, or both, in order to continue to fund operations, and therefore there is substantial doubt about the Company’s ability to continue as a going concern. The Company expects to incur substantial expenses into the foreseeable future for the research, development and commercialization of its current and potential other products. In addition, the Company will require additional financing in order to seek to license or acquire new assets, research and develop any potential patents and the related compounds, and obtain any further intellectual property that the Company may APIs AC5® June 28, 2018 (“ 2018 2018 not 2018 20% 6 2018 The continued spread of coronavirus and geopolitical conflicts, including the recent war in Ukraine, as well as uncertain market conditions, may may The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The consolidated financial statements do not |
Note 3 - Property and Equipme_3
Note 3 - Property and Equipment (Tables) | 9 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Sep. 30, 2021 | |
Notes Tables | ||
Property, Plant and Equipment [Table Text Block] | Estimated Useful June 30, September 30, Life (years) 2022 2021 Furniture and fixtures 5 $ 9,357 $ 9,357 Leasehold improvements Life of Lease 8,983 8,983 Computer equipment 3 14,416 14,416 Lab equipment 5 1,000 1,000 33,756 33,756 Less – accumulated depreciation 30,913 28,516 Property and equipment, net $ 2,843 $ 5,240 | Estimated Useful September 30, September 30, Life (years) 2021 2020 Furniture and fixtures 5 $ 9,357 $ 9,357 Leasehold improvements Life of Lease $ 8,983 $ 8,983 Computer equipment 3 $ 14,416 $ 11,141 Lab equipment 5 $ 1,000 $ 1,000 33,756 30,481 Less - accumulated depreciation 28,516 25,929 Property and equipment, net $ 5,240 $ 4,552 |
Note 4 - Income Taxes (Tables)
Note 4 - Income Taxes (Tables) | 12 Months Ended |
Sep. 30, 2021 | |
Notes Tables | |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | 2021 2020 Net operating loss carryforwards $ 10,022,020 $ 8,451,214 Capitalized expenditures 1,703,849 1,782,185 Research and experimentation credit carryforwards 946,158 928,734 Stock based compensation 2,352,432 2,321,519 Property and Equipment 2,740 3,152 Accrued expenses 57,812 18,518 Inventory allowance 62,946 16,497 Gross deferred tax assets 15,147,957 13,521,819 Deferred tax asset valuation allowance (15,147,957 ) (13,521,819 Net deferred tax assets $ - $ - |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | 2021 2020 Expected income tax (benefit) at federal statutory rate 21.00 % 21.00 % Increase/(Decrease) due to: State Taxes - Net of federal benefit 5.80 % 7.08 % Permanent Differences: Key man life insurance (0.01 )% (0.01 )% R&D, taken as a credit (0.29 )% (0.51 )% Adjustment to fair value of derivative 0.37 % 3.04 % PPP Loan Forgiveness 0.60 % 0.00 % Other (1.41 )% 0.51 % Change in Valuation Allowance (26.06 )% (31.11 )% Total Income Tax Provision / Benefit - % - % |
Note 5 - Inventories (Tables)
Note 5 - Inventories (Tables) | 9 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Sep. 30, 2021 | |
Notes Tables | ||
Schedule of Inventory, Current [Table Text Block] | June 30, September 30, 2022 2021 Finished goods $ — $ 249,571 Goods-in-process 1,428,264 844,194 Total $ 1,428,264 $ 1,093,765 | September 30, September 30, 2021 2020 Finished Goods $ 249,571 $ - Goods-in-process 844,194 967,993 Total $ 1,093,765 $ 967,993 |
Note 7 - Derivative Liabiliti_3
Note 7 - Derivative Liabilities (Tables) | 12 Months Ended |
Sep. 30, 2021 | |
Notes Tables | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | Fair Value Measurements Using Significant Unobservable Inputs - September 30, 2021 (Level 3) Series F Series G Series H Beginning balance at September 30, 2020 $ 1,000,000 $ 748,275 $ 568,144 Issuances - - - Adjustments to estimated fair value - - (108,944 Ending balance at September 30, 2021 $ 1,000,000 $ 748,275 $ 459,200 Fair Value Measurements Using Significant Unobservable Inputs - September 30, 2020 (Level 3) Series F Series G Series H Beginning balance at September 30, 2019 $ 1,000,000 $ 748,275 $ 1,247,415 Issuances - - - Adjustments to estimated fair value - - (679,271 Ending balance at September 30, 2020 $ 1,000,000 $ 748,275 $ 568,144 |
Schedule Of Assumptions Used To Value Derivative Liability [Table Text Block] | Series F Series G Series H Closing price per share of common stock $ 0.12 $ 0.12 $ 0.12 Exercise price per share $ 0.75 $ 0.7 $ 0.4 Expected volatility 90.28 % 87.4 % 86.59 % Risk-free interest rate 0.04 % 0.19 % 0.41 % Dividend yield — — — Remaining expected term of underlying securities (years) 0.34 1.7 2.58 Series F Series G Series H Closing price per share of common stock $ 0.17 $ 0.17 $ 0.17 Exercise price per share $ 0.75 $ 0.7 $ 0.4 Expected volatility 84.17 % 83.31 % 82.24 % Risk-free interest rate 0.13 % 0.15 % 0.22 % Dividend yield — — — Remaining expected term of underlying securities (years) 1.35 2.71 3.6 |
Note 12 - Stock-based Compens_2
Note 12 - Stock-based Compensation (Tables) | 9 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Sep. 30, 2021 | |
Notes Tables | ||
Share-Based Payment Arrangement, Option, Activity [Table Text Block] | Option Shares Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at September 30, 2021 24,899,014 $ 0.29 1.83 $ 140,151 Awarded 675,000 0.06 — — Forfeited/Cancelled (3,083,818 ) 0.33 — — Outstanding at June 30, 2022 22,490,196 0.28 1.47 — Vested at June 30, 2022 19,135,976 0.31 1.70 — Vested and expected to vest at June 30, 2022 22,490,196 0.28 1.47 — | Weighted Average Weighted Option Average Remaining Aggregate Shares Exercise Contractual Intrinsic Outstanding Price Term (years) Value Outstanding at September 30, 2020 18,248,346 $ 0.36 2.59 $ 79,330 Awarded 7,375,000 $ 0.12 - - Forfeited/Cancelled (724,332 ) $ 0.44 - - Outstanding at September 30, 2021 24,899,014 $ 0.29 1.83 $ 140,151 Vested at September 30, 2021 18,814,908 $ 0.35 2.17 $ 17,122 Vested and expected to vest at September 30, 2021 24,899,014 $ 0.29 1.83 $ 140,151 |
Nonvested Restricted Stock Shares Activity [Table Text Block] | 2021 2020 Non Vested at September 30, 2020 and 2019 - 965,000 Awarded 1,000,000 - Vested (550,000 ) (965,000 ) Forfeited - - Non Vested at September 30, 2021 and 2020 450,000 - | |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] | 2021 2020 Non Vested at September 30, 2020 and 2019 $ - $ 0.43 Awarded 0.13 - Vested (0.16 ) (0.43 ) Forfeited - - Non Vested at September 30, 2021 and 2020 $ 0.10 $ - |
Note 3 - Property and Equipme_4
Note 3 - Property and Equipment (10Q) (Tables) | 9 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Sep. 30, 2021 | |
Notes Tables | ||
Property, Plant and Equipment [Table Text Block] | Estimated Useful June 30, September 30, Life (years) 2022 2021 Furniture and fixtures 5 $ 9,357 $ 9,357 Leasehold improvements Life of Lease 8,983 8,983 Computer equipment 3 14,416 14,416 Lab equipment 5 1,000 1,000 33,756 33,756 Less – accumulated depreciation 30,913 28,516 Property and equipment, net $ 2,843 $ 5,240 | Estimated Useful September 30, September 30, Life (years) 2021 2020 Furniture and fixtures 5 $ 9,357 $ 9,357 Leasehold improvements Life of Lease $ 8,983 $ 8,983 Computer equipment 3 $ 14,416 $ 11,141 Lab equipment 5 $ 1,000 $ 1,000 33,756 30,481 Less - accumulated depreciation 28,516 25,929 Property and equipment, net $ 5,240 $ 4,552 |
Note 4 - Inventories (Tables)
Note 4 - Inventories (Tables) | 9 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Sep. 30, 2021 | |
Notes Tables | ||
Schedule of Inventory, Current [Table Text Block] | June 30, September 30, 2022 2021 Finished goods $ — $ 249,571 Goods-in-process 1,428,264 844,194 Total $ 1,428,264 $ 1,093,765 | September 30, September 30, 2021 2020 Finished Goods $ 249,571 $ - Goods-in-process 844,194 967,993 Total $ 1,093,765 $ 967,993 |
Note 5 - Stock-based Compensa_2
Note 5 - Stock-based Compensation (Tables) | 9 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Sep. 30, 2021 | |
Notes Tables | ||
Share-Based Payment Arrangement, Option, Activity [Table Text Block] | Option Shares Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at September 30, 2021 24,899,014 $ 0.29 1.83 $ 140,151 Awarded 675,000 0.06 — — Forfeited/Cancelled (3,083,818 ) 0.33 — — Outstanding at June 30, 2022 22,490,196 0.28 1.47 — Vested at June 30, 2022 19,135,976 0.31 1.70 — Vested and expected to vest at June 30, 2022 22,490,196 0.28 1.47 — | Weighted Average Weighted Option Average Remaining Aggregate Shares Exercise Contractual Intrinsic Outstanding Price Term (years) Value Outstanding at September 30, 2020 18,248,346 $ 0.36 2.59 $ 79,330 Awarded 7,375,000 $ 0.12 - - Forfeited/Cancelled (724,332 ) $ 0.44 - - Outstanding at September 30, 2021 24,899,014 $ 0.29 1.83 $ 140,151 Vested at September 30, 2021 18,814,908 $ 0.35 2.17 $ 17,122 Vested and expected to vest at September 30, 2021 24,899,014 $ 0.29 1.83 $ 140,151 |
Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] | Nine Months Ended June 30, 2022 June 30, 2021 Non Vested at September 30, 2021 and 2020 450,000 — Awarded — 550,000 Vested (275,000 ) (550,000 ) Forfeited — — Non Vested at June 30, 2022 and 2021 175,000 — Nine Months Ended June 30, 2022 June 30, 2021 Non Vested at September 30, 2021 and 2020 $ 0.10 $ — Awarded — 0.19 Vested (0.10 ) (0.19 ) Forfeited — — Non Vested at June 30, 2022 and 2021 $ 0.10 $ — |
Note 7 - Derivative Liabiliti_4
Note 7 - Derivative Liabilities (10Q) (Tables) | 9 Months Ended |
Jun. 30, 2022 | |
Notes Tables | |
Schedule of Derivative Liabilities at Fair Value [Table Text Block] | Fair Value Measurements Using Significant Unobservable Inputs - Nine Months Ended June 30, 2022 (Level 3) Series F Series G Series H Beginning balance at September 30, 2021 $ 1,000,000 $ 748,275 $ 459,200 Issuances — — — Adjustments to estimated fair value (1,000,000 ) — — Ending balance at June 30, 2022 $ — $ 748,275 $ 459,200 Fair Value Measurements Using Significant Unobservable Inputs Year Ended September 30, 2021 (Level 3) Series F Series G Series H Beginning balance at September 30, 2020 $ 1,000,000 $ 748,275 $ 568,144 Issuances — — — Adjustments to estimated fair value — — (108,944 ) Ending balance at September 30, 2021 $ 1,000,000 $ 748,275 $ 459,200 |
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] | Series G Series H Closing price per share of Common Stock $ 0.046 $ 0.046 Exercise price per share $ 0.70 $ 0.40 Expected volatility 106.18 % 95.85 % Risk-free interest rate 2.80 % 2.92 % Dividend yield — — Remaining expected term of underlying securities (years) 0.94 1.83 Series F Series G Series H Closing price per share of Common Stock $ 0.12 $ 0.12 $ 0.12 Exercise price per share $ 0.75 $ 0.70 $ 0.40 Expected volatility 90.28 % 87.40 % 86.59 % Risk-free interest rate 0.04 % 0.19 % 0.41 % Dividend yield — — — Remaining expected term of underlying securities (years) 0.34 1.70 2.58 |
Note 2 - Summary Of Significa_3
Note 2 - Summary Of Significant Accounting Policies (Details Textual) - USD ($) | Jun. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2020 |
Cash Equivalents, at Carrying Value, Total | $ 0 | $ 0 | $ 0 |
Operating Lease, Right-of-Use Asset | 0 | 39,000 | |
Operating Lease, Liability, Total | $ 0 | $ 39,000 |
Note 3 - Property and Equipme_5
Note 3 - Property and Equipment (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Sep. 30, 2021 | Sep. 30, 2020 | |
Depreciation, Total | $ 799 | $ 799 | $ 2,397 | $ 1,788 | $ 2,587 | $ 6,926 |
Note 3 - Property and Equipme_6
Note 3 - Property and Equipment - Property and Equipment (Details) - USD ($) | 9 Months Ended | 12 Months Ended | |
Jun. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2020 | |
Property and equipment, gross | $ 33,756 | $ 33,756 | $ 30,481 |
Less - accumulated depreciation, Total | 30,913 | 28,516 | 25,929 |
Property and equipment, net | $ 2,843 | $ 5,240 | 4,552 |
Furniture and Fixtures [Member] | |||
Estimated useful life (Year) | 5 years | 5 years | |
Property and equipment, gross | $ 9,357 | $ 9,357 | 9,357 |
Leasehold Improvements [Member] | |||
Property and equipment, gross | $ 8,983 | $ 8,983 | 8,983 |
Computer Equipment [Member] | |||
Estimated useful life (Year) | 3 years | 3 years | |
Property and equipment, gross | $ 14,416 | $ 14,416 | 11,141 |
Technology Equipment [Member] | |||
Estimated useful life (Year) | 5 years | ||
Property and equipment, gross | $ 1,000 | $ 1,000 |
Note 4 - Income Taxes (Details
Note 4 - Income Taxes (Details Textual) - USD ($) | 12 Months Ended | |
Sep. 30, 2021 | Sep. 30, 2020 | |
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | $ 37,018,000 | $ 31,119,000 |
Deferred Tax Assets, Operating Loss Carryforwards, State and Local | 36,033,000 | 30,737,000 |
Deferred Tax Assets, Tax Credit Carryforwards, Other | 2,740 | 3,152 |
Deferred Tax Assets, Tax Credit Carryforwards, Research | 946,158 | 928,734 |
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | 1,626,000 | 1,459,000 |
Expire In 2026 [Member] | ||
Deferred Tax Assets, Operating Loss Carryforwards, State and Local | 21,750,000 | |
Expire In 2028 [Member] | ||
Deferred Tax Assets, Tax Credit Carryforwards, Other | 15,268,000 | 9,369,000 |
Deferred Tax Assets, Tax Credit Carryforwards, Research | 643,000 | 557,000 |
Expire In 2023 [Member] | ||
Deferred Tax Assets, Tax Credit Carryforwards, Research | $ 384,000 | $ 345,000 |
Note 4 - Income Taxes - Net Def
Note 4 - Income Taxes - Net Deferred Tax Assets (Details) - USD ($) | Sep. 30, 2021 | Sep. 30, 2020 |
Net operating loss carryforwards | $ 10,022,020 | $ 8,451,214 |
Capitalized expenditures | 1,703,849 | 1,782,185 |
Research and experimentation credit carryforwards | 946,158 | 928,734 |
Stock based compensation | 2,352,432 | 2,321,519 |
Property and Equipment | 2,740 | 3,152 |
Accrued expenses | 57,812 | 18,518 |
Inventory allowance | 62,946 | 16,497 |
Gross deferred tax assets | 15,147,957 | 13,521,819 |
Deferred tax asset valuation allowance | (15,147,957) | (13,521,819) |
Net deferred tax assets | $ 0 | $ 0 |
Note 4 - Income Taxes - Computa
Note 4 - Income Taxes - Computation of Provision (benefits) Income Taxes from Statutory Federal Income Tax Rate (Details) | 12 Months Ended | |
Sep. 30, 2021 | Sep. 30, 2020 | |
Expected income tax (benefit) at federal statutory rate | 21% | 21% |
Increase/(Decrease) due to: | ||
State Taxes - Net of federal benefit | 5.80% | 7.08% |
Permanent Differences: | ||
Key man life insurance | (0.01%) | (0.01%) |
R&D, taken as a credit | (0.29%) | (0.51%) |
Adjustment to fair value of derivative | 0.37% | 3.04% |
PPP Loan Forgiveness | 0.60% | 0% |
Other | (1.41%) | 0.51% |
Change in Valuation Allowance | (26.06%) | (31.11%) |
Total Income Tax Provision / Benefit | 0% | 0% |
Note 5 - Inventories - Inventor
Note 5 - Inventories - Inventories (Details) - USD ($) | Jun. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2020 |
Finished Goods | $ 249,571 | $ 0 | |
Goods-in-process | 844,194 | 967,993 | |
Total | $ 1,428,264 | $ 1,093,765 | $ 967,993 |
Note 6 - Registered Direct Of_3
Note 6 - Registered Direct Offerings (Details Textual) | 12 Months Ended | ||||
May 12, 2019 $ / shares shares | Jul. 02, 2018 $ / shares shares | Feb. 24, 2017 $ / shares shares | Sep. 30, 2021 shares | Sep. 30, 2016 USD ($) | |
Shelf Registration Statement, Maximum Amount Authorized | $ | $ 50,000,000 | ||||
Class Of Series F Warrant [Member] | |||||
Class of Warrant or Right, Exercised (in shares) | 0 | ||||
Class Of Warrant Or Right Acquired Upon Exercise (in shares) | 5,591,664 | ||||
Class Of Series G Warrant [Member] | |||||
Class Of Warrant Or Right Acquired Upon Exercise (in shares) | 6,802,500 | ||||
Class Of Series H Warrant [Member] | |||||
Class Of Warrant Or Right Acquired Upon Exercise (in shares) | 8,615,384 | ||||
Registered Direct Offering 2017 [Member] | |||||
Stock Issued During Period, Shares, New Issues (in shares) | 10,166,664 | ||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 0.60 | ||||
Registered Direct Offering 2017 [Member] | Class Of Series F Warrant [Member] | |||||
Percentage of Warrants Per Unit | 55 | ||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.75 | ||||
Registered Direct Offering 2018 [Member] | |||||
Stock Issued During Period, Shares, New Issues (in shares) | 9,070,000 | ||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 0.50 | ||||
Number Of Accredited Investors | 8 | ||||
Registered Direct Offering 2018 [Member] | Class Of Series G Warrant [Member] | |||||
Percentage of Warrants Per Unit | 75 | ||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.70 | ||||
Registered Direct Offering 2019 [Member] | |||||
Stock Issued During Period, Shares, New Issues (in shares) | 8,615,384 | ||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 0.325 | ||||
Number Of Accredited Investors | 5 | ||||
Registered Direct Offering 2019 [Member] | Class Of Series H Warrant [Member] | |||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.40 |
Note 7 - Derivative Liabiliti_5
Note 7 - Derivative Liabilities (Details Textual) - USD ($) | 12 Months Ended | |
Sep. 30, 2021 | Sep. 30, 2020 | |
Derivative Liability, Total | $ 1,628,113 | |
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total | 108,944 | $ 679,271 |
Series F Warrants Relating To 2017 Securities Purchase Agreement [Member] | ||
Cash Price Per Each Common Stock Underlying Warrants | 0.18 | |
Series G Warrants Relating To 2018 Securities Purchase Agreement [Member] | ||
Cash Price Per Each Common Stock Underlying Warrants | 0.11 | |
Series H Warrants Relating To 2019 Securities Purchase Agreement [Member] | ||
Cash Price Per Each Common Stock Underlying Warrants | $ 0.0533 |
Note 7 - Derivative Liabiliti_6
Note 7 - Derivative Liabilities - Fair Value Measurements (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($) | 12 Months Ended | |
Sep. 30, 2021 | Sep. 30, 2020 | |
Series F Warrants Relating To 2017 Securities Purchase Agreement [Member] | ||
Beginning balance at September 30, 2020 | $ 1,000,000 | $ 1,000,000 |
Adjustments to estimated fair value | 0 | 0 |
Ending balance at September 30, 2021 | 1,000,000 | 1,000,000 |
Series G Warrants Relating To 2018 Securities Purchase Agreement [Member] | ||
Beginning balance at September 30, 2020 | 748,275 | 748,275 |
Adjustments to estimated fair value | 0 | |
Ending balance at September 30, 2021 | 748,275 | 748,275 |
Series H Warrants Relating To 2019 Securities Purchase Agreement [Member] | ||
Beginning balance at September 30, 2020 | 568,144 | 1,247,415 |
Adjustments to estimated fair value | (108,944) | (679,271) |
Ending balance at September 30, 2021 | $ 459,200 | $ 568,144 |
Note 7 - Derivative Liabiliti_7
Note 7 - Derivative Liabilities - Derivative Liabilities (Details) | 12 Months Ended | ||
Sep. 30, 2021 $ / shares | Sep. 30, 2020 $ / shares | Jun. 30, 2022 $ / shares | |
Common Stock, Par Value (in dollars per share) | $ 0.001 | $ 0.001 | $ 0.001 |
Series F Warrants Relating To 2017 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member] | |||
Common Stock, Par Value (in dollars per share) | $ 0.12 | $ 0.17 | |
Series F Warrants Relating To 2017 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member] | Measurement Input, Exercise Price [Member] | |||
Measurement Input | 0.75 | 0.75 | |
Series F Warrants Relating To 2017 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member] | Measurement Input, Price Volatility [Member] | |||
Measurement Input | 90.28 | 84.17 | |
Series F Warrants Relating To 2017 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||
Measurement Input | 0.04 | 0.13 | |
Series F Warrants Relating To 2017 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member] | Measurement Input, Expected Term [Member] | |||
Remaining expected term of underlying securities (years) (Year) | 4 months 2 days | 1 year 4 months 6 days | |
Series G Warrants Relating To 2018 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member] | |||
Common Stock, Par Value (in dollars per share) | $ 0.12 | $ 0.17 | |
Series G Warrants Relating To 2018 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member] | Measurement Input, Exercise Price [Member] | |||
Measurement Input | 0.7 | 0.7 | |
Series G Warrants Relating To 2018 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member] | Measurement Input, Price Volatility [Member] | |||
Measurement Input | 87.4 | 83.31 | |
Series G Warrants Relating To 2018 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||
Measurement Input | 0.19 | 0.15 | |
Series G Warrants Relating To 2018 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member] | Measurement Input, Expected Term [Member] | |||
Remaining expected term of underlying securities (years) (Year) | 1 year 8 months 12 days | 2 years 8 months 15 days | |
Series H Warrants Relating To 2019 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member] | |||
Common Stock, Par Value (in dollars per share) | $ 0.12 | $ 0.17 | |
Series H Warrants Relating To 2019 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member] | Measurement Input, Exercise Price [Member] | |||
Measurement Input | 0.4 | 0.4 | |
Series H Warrants Relating To 2019 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member] | Measurement Input, Price Volatility [Member] | |||
Measurement Input | 86.59 | 82.24 | |
Series H Warrants Relating To 2019 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||
Measurement Input | 0.41 | 0.22 | |
Series H Warrants Relating To 2019 Securities Purchase Agreement [Member] | Derivative Financial Instruments, Liabilities [Member] | Measurement Input, Expected Term [Member] | |||
Remaining expected term of underlying securities (years) (Year) | 2 years 6 months 29 days | 3 years 7 months 6 days |
Note 8 - October 2019 Registe_3
Note 8 - October 2019 Registered Direct Offering (Details Textual) | 12 Months Ended | |||
Oct. 18, 2019 USD ($) $ / shares shares | Oct. 16, 2019 $ / shares shares | Oct. 10, 2019 USD ($) | Sep. 30, 2021 shares | |
Placement Agent Warrants [Member] | ||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares | 1,071,429 | |||
Class of Series I Warrant [Member] | ||||
Stock Issued During Period, Shares, New Issues (in shares) | shares | 0 | |||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares | 14,285,714 | |||
Proceeds from Subscribed, Unissued Common Stock and Warrants | $ | $ 2,500,000 | |||
Payments of Stock Issuance Costs | $ | $ 158,000 | |||
Class of Series I Warrant [Member] | Minimum [Member] | ||||
Percentage of Fee on Gross Proceeds of Warrants | 6 | |||
Class of Series I Warrant [Member] | Maximum [Member] | ||||
Percentage of Fee on Gross Proceeds of Warrants | 8.2 | |||
Registered Direct Offering October 2019 [Member] | ||||
Stock Issued During Period, Shares, New Issues (in shares) | shares | 14,285,714 | 14,285,714 | ||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 0.175 | |||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.22 | |||
Proceeds from Subscribed, Unissued Common Stock and Warrants | $ | $ 2,500,000 | |||
Payments of Financing Costs, Total | $ | 333,000 | |||
Payments of Stock Issuance Costs | $ | $ 158,000 | |||
Registered Direct Offering October 2019 [Member] | Placement Agent Warrants [Member] | ||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.21875 | |||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares | 1,071,429 | |||
Warrants and Rights Outstanding, Term (Year) | 5 years |
Note 9 - 2021 Registered Dire_3
Note 9 - 2021 Registered Direct Offering (Details Textual) | 12 Months Ended | ||||||
Feb. 17, 2021 shares | Feb. 11, 2021 USD ($) $ / shares shares | Feb. 08, 2021 | Sep. 30, 2021 $ / shares shares | Jun. 30, 2022 $ / shares shares | Jun. 30, 2021 shares | Sep. 30, 2020 $ / shares | |
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.001 | $ 0.001 | $ 0.001 | ||||
Series K Warrant [Member] | |||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 32,343,754 | 32,343,754 | |||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.17 | ||||||
Warrants and Rights Outstanding, Term (Year) | 5 years 6 months | ||||||
Placement Agent 2 Warrants [Member] | |||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 3,234,375 | 3,234,375 | |||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.20 | ||||||
Registered Direct Offering 2021 [Member] | |||||||
Stock Issued During Period, Shares, New Issues (in shares) | 43,125,004 | 43,125,004 | |||||
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.001 | ||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 0.16 | ||||||
Payments of Stock Issuance Costs | $ | $ 700,000 | ||||||
Percentage Of Fee On Gross Proceeds From Investors Participating in 2021 Financing | 7.5 | ||||||
Percentage Of Fee On Gross Proceeds From Investors Participating with Pre-existing Relationships | 6 | ||||||
One-Time Non-Accountable Expense Fee | $ | $ 10,000 | ||||||
Maximum Fees And Expenses Of Legal Counsel And Other Out-Of-Pocket Expenses | $ | 50,000 | ||||||
Clearing Expenses | $ | $ 10,000 | ||||||
Placement Agent's Fees, Percent of Warrants to Purchase Aggregate Number of Shares Sold | 7.5 | ||||||
Registered Direct Offering 2021 [Member] | Series K Warrant [Member] | |||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 32,343,754 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.17 | ||||||
Warrants and Rights Outstanding, Term (Year) | 5 years 6 months | ||||||
Proceeds from Issuance or Sale of Equity, Total | $ | $ 6.9 | ||||||
Class of Warrant or Right, Outstanding (in shares) | 32,343,754 | ||||||
Registered Direct Offering 2021 [Member] | Placement Agent 2 Warrants [Member] | |||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 3,234,375 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.20 | ||||||
Class of Warrant or Right, Exercised (in shares) | 0 | ||||||
Class of Warrant or Right, Outstanding (in shares) | 3,234,375 |
Note 10 - Convertible Notes (De
Note 10 - Convertible Notes (Details Textual) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||||||
Nov. 06, 2020 USD ($) $ / shares shares | Jun. 22, 2020 USD ($) $ / shares shares | Jun. 04, 2020 USD ($) $ / shares shares | Jun. 03, 2020 USD ($) | Jun. 30, 2020 shares | Jun. 30, 2022 USD ($) $ / shares | Jun. 30, 2021 USD ($) | Jun. 30, 2022 USD ($) $ / shares | Jun. 30, 2021 USD ($) | Sep. 30, 2021 USD ($) $ / shares | Sep. 30, 2020 USD ($) $ / shares | |
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.001 | |||||||
Proceeds from Warrant Exercises | $ | $ 0 | $ 932,728 | |||||||||
Interest Expense, Total | $ | $ 39,890 | $ 40,186 | $ 119,671 | $ 110,202 | 150,531 | 18,534 | |||||
Series D Warrants [Member] | The 2015 Private Placement [Member] | |||||||||||
Proceeds from Warrant Exercises | $ | $ 82,000 | $ 850,000 | |||||||||
Common Stock Issuance Upon Exercise Of Warrants (in shares) | shares | 454,546 | 4,727,273 | |||||||||
Series J Warrants [Member] | The 2015 Private Placement [Member] | |||||||||||
Common Stock Issuance Upon Exercise Of Warrants (in shares) | shares | 3,375,000 | 340,910 | 3,545,454 | ||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.25 | $ 0.25 | |||||||||
Warrants and Rights Outstanding, Term (Year) | 30 years | 1 year | 1 year | ||||||||
Convertible Notes Payable Series One [Member] | |||||||||||
Debt Instrument, Face Amount | $ | $ 1,050,000 | $ 550,000 | |||||||||
Debt Instrument, Term (Year) | 3 years | ||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 0.25 | $ 0.27 | |||||||||
Convertible Notes Payable [Member] | |||||||||||
Debt Conversion, Original Debt, Interest Rate of Debt | 10% | ||||||||||
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.001 | ||||||||||
Debt Instrument, Convertible, Minimum Volume Weighted Average Price Trigger (in dollars per share) | $ / shares | $ 0.32 | ||||||||||
Number of Consecutive Trading Days for Minimum Volume Weighted Average Price Trigger (Year) | 15 years | ||||||||||
Percentage on Unpaid Principal Amount for Outstanding Note Obligations | 35 | ||||||||||
Percentage on Interest for Outstanding Note Obligations | 10 | ||||||||||
Interest Expense, Total | $ | $ 150,000 | $ 18,000 |
Note 11- Payroll Protection P_2
Note 11- Payroll Protection Program Loan (Details Textual) - USD ($) | 12 Months Ended | ||
Apr. 25, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | |
Other Nonoperating Income (Loss) Debt Forgiveness Amount | $ 178,229 | $ 0 | |
Paycheck Protection Program Loan [Member] | |||
Proceeds from Issuance of Debt | $ 176,300 | ||
Debt Instrument, Term (Year) | 2 years | ||
Debt Instrument, Interest Rate, Stated Percentage | 1% | ||
Debt Instrument, Periodic Payment, Total | $ 20,000 | ||
Other Nonoperating Income (Loss) Debt Forgiveness Amount | $ 178,000 |
Note 12 - Stock-based Compens_3
Note 12 - Stock-based Compensation (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||||||||||
Oct. 01, 2021 | Sep. 27, 2021 | Jul. 30, 2021 | Jan. 27, 2021 | Oct. 14, 2020 | Jul. 19, 2018 | Jun. 18, 2013 | Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Sep. 30, 2021 | Sep. 30, 2020 | Oct. 01, 2020 | |
Common Stock, Shares Authorized (in shares) | 800,000,000 | 800,000,000 | 800,000,000 | 800,000,000 | ||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 675,000 | 7,375,000 | ||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum | 79.44% | |||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum | 119.44% | |||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum | 0.13% | |||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum | 2.85% | |||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0% | |||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year) | 5 years 7 months 6 days | |||||||||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 230,633 | $ 230,633 | ||||||||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 1 year 9 months 14 days | |||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in shares) | 18,814,908 | |||||||||||||
Restricted Stock [Member] | ||||||||||||||
Share-Based Payment Arrangement, Expense | $ 10,000 | $ 0 | $ 30,000 | $ 104,000 | ||||||||||
Non Employee Restricted Shares [Member] | ||||||||||||||
Share-Based Payment Arrangement, Expense | $ 105,000 | $ 220,000 | ||||||||||||
Research and Development Expense [Member] | ||||||||||||||
Share-Based Payment Arrangement, Expense | 124,000 | 288,000 | ||||||||||||
General and Administrative Expense [Member] | ||||||||||||||
Share-Based Payment Arrangement, Expense | $ 267,000 | 390,000 | ||||||||||||
Employees and Directors [Member] | ||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 24,479,212 | |||||||||||||
Consultants [Member] | ||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 9,792,500 | |||||||||||||
Employees Directors And Consultants [Member] | ||||||||||||||
Share-Based Payment Arrangement, Expense | $ 391,000 | $ 678,000 | ||||||||||||
Employees [Member] | Restricted Stock [Member] | ||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares) | 150,000 | |||||||||||||
The 2013 Plan [Member] | ||||||||||||||
Common Stock, Shares Authorized (in shares) | 31,114,256 | 34,114,256 | ||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) | 3,000,000 | 3,000,000 | ||||||||||||
Increase In Aggregate Number Of Shares (in shares) | 3,000,000 | |||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 0 | 0 | ||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) | 5,508,158 | 5,508,158 | 99,340 | |||||||||||
Share-Based Payment Arrangement, Expense | $ 81,000 | 94,000 | $ 367,000 | 269,000 | ||||||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 153,000 | |||||||||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 2 years 5 months 19 days | |||||||||||||
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount | $ 43,000 | |||||||||||||
The 2013 Plan [Member] | Restricted Stock [Member] | Share-Based Payment Arrangement, Tranche One [Member] | ||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in shares) | 50,000 | |||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage | 100% | |||||||||||||
The 2013 Plan [Member] | Research and Development Expense [Member] | ||||||||||||||
Share-Based Payment Arrangement, Expense | 29,000 | 35,000 | 123,000 | 89,000 | ||||||||||
The 2013 Plan [Member] | General and Administrative Expense [Member] | ||||||||||||||
Share-Based Payment Arrangement, Expense | $ 52,000 | $ 59,000 | $ 245,000 | $ 180,000 | ||||||||||
The 2013 Plan [Member] | Employees and Directors [Member] | ||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 475,000 | 5,300,000 | ||||||||||||
The 2013 Plan [Member] | Consultants [Member] | ||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 200,000 | 2,075,000 | ||||||||||||
The 2013 Plan [Member] | Consultants [Member] | Restricted Stock [Member] | ||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares) | 300,000 | 500,000 | 50,000 | |||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) | 90 years | |||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Other (in shares) | 220,000 | |||||||||||||
The 2013 Plan [Member] | Consultants [Member] | Restricted Stock [Member] | Share-Based Payment Arrangement, Tranche One [Member] | ||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage | 8.33% | |||||||||||||
The 2013 Plan [Member] | Board Of Directors And Management [Member] | Restricted Stock [Member] | ||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares) | 745,000 |
Note 12 - Stock-based Compens_4
Note 12 - Stock-based Compensation - Stock Compensation Activity (Details) - USD ($) | 9 Months Ended | 12 Months Ended | |
Jun. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2020 | |
Outstanding (in shares) | 24,899,014 | 18,248,346 | |
Outstanding, weighted average exercise price (in dollars per share) | $ 0.29 | $ 0.36 | |
Outstanding, weighted average remaining contractual term (Year) | 1 year 5 months 19 days | 1 year 9 months 29 days | 2 years 7 months 2 days |
Outstanding, aggregate intrinsic value | $ 0 | $ 140,151 | $ 79,330 |
Awarded, shares (in shares) | 675,000 | 7,375,000 | |
Awarded, weighted average exercise price (in dollars per share) | $ 0.06 | $ 0.12 | |
Forfeited/Cancelled, shares (in shares) | (724,332) | ||
Forfeited/Cancelled (in dollars per share) | $ 0.44 | ||
Outstanding (in shares) | 22,490,196 | 24,899,014 | 18,248,346 |
Outstanding, weighted average exercise price (in dollars per share) | $ 0.28 | $ 0.29 | $ 0.36 |
Vested at September 30, 2021 (in shares) | 18,814,908 | ||
Vested at September 30, 2021 (in dollars per share) | $ 0.35 | ||
Vested at September 30, 2021 (Year) | 2 years 2 months 1 day | ||
Vested at September 30, 2021 | $ 17,122 | ||
Vested and expected to vest (in shares) | 22,490,196 | 24,899,014 | |
Vested and expected to vest at September 30, 2021 (in dollars per share) | $ 0.29 | ||
Vested and expected to vest at September 30, 2021 (Year) | 1 year 9 months 29 days | ||
Vested and expected to vest at September 30, 2021 | $ 140,151 |
Note 12 - Stock-based Compens_5
Note 12 - Stock-based Compensation - Restricted Stock Activity (Details) - shares | 12 Months Ended | |
Sep. 30, 2021 | Sep. 30, 2020 | |
Non Vested (in shares) | 0 | |
Non Vested (in shares) | 450,000 | 0 |
The 2013 Plan [Member] | ||
Non Vested (in shares) | 0 | 965,000 |
Awarded (in shares) | 1,000,000 | 0 |
Vested (in shares) | (550,000) | (965,000) |
Forfeited (in shares) | 0 | 0 |
Non Vested (in shares) | 0 |
Note 12 - Stock-based Compens_6
Note 12 - Stock-based Compensation - Restricted Stock Weighted Average Grant Date Fair Value (Details) - $ / shares | 12 Months Ended | |
Sep. 30, 2021 | Sep. 30, 2020 | |
Non Vested (in dollars per share) | $ 0 | $ 0.43 |
Awarded (in dollars per share) | 0.13 | 0 |
Vested (in dollars per share) | (0.16) | (0.43) |
Forfeited (in dollars per share) | 0 | 0 |
Non Vested (in dollars per share) | $ 0.10 | $ 0 |
Note 13 - Commitments and Con_2
Note 13 - Commitments and Contingencies (Details Textual) - USD ($) | 12 Months Ended | ||||
Sep. 30, 2021 | Mar. 31, 2022 | Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2018 | |
Lessee, Operating Lease, Term of Contract (Year) | 3 years | ||||
Accrued Rent | $ 42,000 | $ 21,000 | $ 42,000 | $ 39,600 | $ 38,400 |
Operating Lease, Right-of-Use Asset | 0 | 39,000 | |||
Operating Lease, Liability, Total | $ 0 | $ 39,000 | |||
Patents [Member] | |||||
Finite-Lived Intangible Asset, Useful Life (Year) | 20 years | ||||
M I T Licensing Agreement [Member] | |||||
Contractual Obligation, Total | $ 50,000 |
Note 1 - Basis of Presentatio_2
Note 1 - Basis of Presentation and Description of Business (Details Textual) - $ / shares | Jun. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2020 |
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ 0.001 | $ 0.001 | $ 0.001 |
Note 2 - Summary of Significa_4
Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Sep. 30, 2021 | Sep. 30, 2020 | |
Cash Equivalents, at Carrying Value, Total | $ 0 | $ 0 | $ 0 | $ 0 | ||
Asset Impairment Charges, Total | $ 0 | $ 0 | $ 0 | $ 0 |
Note 3 - Property and Equipme_7
Note 3 - Property and Equipment (10Q) (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Sep. 30, 2021 | Sep. 30, 2020 | |
Depreciation, Total | $ 799 | $ 799 | $ 2,397 | $ 1,788 | $ 2,587 | $ 6,926 |
Note 3 - Property and Equipme_8
Note 3 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) | 9 Months Ended | 12 Months Ended | |
Jun. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2020 | |
Property and equipment, gross | $ 33,756 | $ 33,756 | $ 30,481 |
Less – accumulated depreciation | (30,913) | (28,516) | (25,929) |
Property and equipment, net | $ 2,843 | $ 5,240 | 4,552 |
Furniture and Fixtures [Member] | |||
Estimated useful life (Year) | 5 years | 5 years | |
Property and equipment, gross | $ 9,357 | $ 9,357 | 9,357 |
Leasehold Improvements [Member] | |||
Property and equipment, gross | $ 8,983 | $ 8,983 | 8,983 |
Computer Equipment [Member] | |||
Estimated useful life (Year) | 3 years | 3 years | |
Property and equipment, gross | $ 14,416 | $ 14,416 | $ 11,141 |
Equipment [Member] | |||
Estimated useful life (Year) | 5 years | ||
Property and equipment, gross | $ 1,000 | $ 1,000 |
Note 4 - Inventories - Inventor
Note 4 - Inventories - Inventories (Details) - USD ($) | Jun. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2020 |
Finished goods | $ 0 | $ 249,571 | |
Goods-in-process | 1,428,264 | 844,194 | |
Total | $ 1,428,264 | $ 1,093,765 | $ 967,993 |
Note 5 - Stock-based Compensa_3
Note 5 - Stock-based Compensation (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||||
Oct. 01, 2021 | Jun. 18, 2013 | Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Sep. 30, 2021 | Sep. 30, 2020 | |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 675,000 | 7,375,000 | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares) | 0 | 0 | ||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 230,633 | $ 230,633 | ||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 1 year 9 months 14 days | |||||||
Restricted Stock [Member] | ||||||||
Share-Based Payment Arrangement, Expense | $ 10,000 | $ 0 | $ 30,000 | $ 104,000 | ||||
Research and Development Expense [Member] | ||||||||
Share-Based Payment Arrangement, Expense | $ 124,000 | $ 288,000 | ||||||
General and Administrative Expense [Member] | ||||||||
Share-Based Payment Arrangement, Expense | $ 267,000 | $ 390,000 | ||||||
Employees and Directors [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 24,479,212 | |||||||
Consultants [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 9,792,500 | |||||||
The 2013 Plan [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 34,114,256 | 31,114,256 | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) | 3,000,000 | 3,000,000 | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 0 | 0 | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) | 5,508,158 | 5,508,158 | 99,340 | |||||
Share-Based Payment Arrangement, Expense | $ 81,000 | 94,000 | $ 367,000 | 269,000 | ||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 153,000 | |||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 2 years 5 months 19 days | |||||||
The 2013 Plan [Member] | Research and Development Expense [Member] | ||||||||
Share-Based Payment Arrangement, Expense | 29,000 | 35,000 | 123,000 | 89,000 | ||||
The 2013 Plan [Member] | General and Administrative Expense [Member] | ||||||||
Share-Based Payment Arrangement, Expense | $ 52,000 | $ 59,000 | $ 245,000 | $ 180,000 | ||||
The 2013 Plan [Member] | Employees and Directors [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 475,000 | 5,300,000 | ||||||
The 2013 Plan [Member] | Consultants [Member] | ||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 200,000 | 2,075,000 |
Note 5 - Stock-based Compensa_4
Note 5 - Stock-based Compensation - Stock Compensation Activity (Details) - USD ($) | 9 Months Ended | 12 Months Ended | |
Jun. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2020 | |
Outstanding (in shares) | 24,899,014 | 18,248,346 | |
Outstanding, weighted average exercise price (in dollars per share) | $ 0.29 | $ 0.36 | |
Outstanding, weighted average remaining contractual term (Year) | 1 year 5 months 19 days | 1 year 9 months 29 days | 2 years 7 months 2 days |
Outstanding, aggregate intrinsic value | $ 0 | $ 140,151 | $ 79,330 |
Awarded (in shares) | 675,000 | 7,375,000 | |
Awarded, weighted average exercise price (in dollars per share) | $ 0.06 | $ 0.12 | |
Forfeited/Cancelled (in shares) | (3,083,818) | ||
Forfeited/Cancelled, weighted average exercise price (in dollars per share) | $ 0.33 | ||
Outstanding (in shares) | 22,490,196 | 24,899,014 | 18,248,346 |
Outstanding, weighted average exercise price (in dollars per share) | $ 0.28 | $ 0.29 | $ 0.36 |
Vested (in shares) | 19,135,976 | ||
Vested, weighted average exercise price (in dollars per share) | $ 0.31 | ||
Vested, weighted average remaining contractual term (Year) | 1 year 8 months 12 days | ||
Vested and expected to vest (in shares) | 22,490,196 | 24,899,014 | |
Vested and expected to vest, weighted average exercise price (in dollars per share) | $ 0.28 | ||
Vested and expected to vest, weighted average remaining contractual term (Year) | 1 year 5 months 19 days | ||
Vested and expected to vest, aggregate intrinsic value | $ 0 |
Note 5 - Stock-based Compensa_5
Note 5 - Stock-based Compensation - Restricted Stock Activity (Details) - $ / shares | 9 Months Ended | 12 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Sep. 30, 2021 | Sep. 30, 2020 | |
Non Vested (in shares) | 450,000 | 0 | 0 | |
Non Vested (in shares) | 450,000 | 0 | ||
Non Vested (in dollars per share) | $ 0.10 | $ 0 | $ 0 | $ 0.43 |
Awarded (in dollars per share) | 0.13 | 0 | ||
Vested (in dollars per share) | (0.16) | (0.43) | ||
Forfeited, weighted average fair value (in dollars per share) | 0 | 0 | ||
Non Vested (in dollars per share) | $ 0.10 | $ 0 | ||
Restricted Stock [Member] | ||||
Non Vested (in shares) | 450,000 | 0 | 0 | |
Awarded (in shares) | 0 | 550,000 | ||
Vested (in shares) | (275,000) | (550,000) | ||
Forfeited (in shares) | 0 | 0 | ||
Non Vested (in shares) | 175,000 | 0 | 450,000 | 0 |
Non Vested (in dollars per share) | $ 0.10 | $ 0 | $ 0 | |
Awarded (in dollars per share) | 0 | 0.19 | ||
Vested (in dollars per share) | (0.10) | (0.19) | ||
Forfeited, weighted average fair value (in dollars per share) | 0 | 0 | ||
Non Vested (in dollars per share) | $ 0.10 | $ 0 | $ 0.10 | $ 0 |
Note 6 - Registered Direct Of_4
Note 6 - Registered Direct Offerings That Created Derivative Liabilities (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | |||||||
May 12, 2019 | Jun. 28, 2018 | Feb. 20, 2017 | Jun. 30, 2022 | Mar. 31, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Sep. 30, 2016 | |
Series F Warrant [Member] | |||||||||
Warrants and Rights, Percent of Stock Oustanding Callable | 55% | ||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.75 | ||||||||
Class of Warrant or Right, Expired During Period (in shares) | 5,591,664 | ||||||||
Series G Warrant [Member] | |||||||||
Warrants and Rights, Percent of Stock Oustanding Callable | 75% | ||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.70 | ||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 6,802,500 | 6,802,500 | |||||||
Series H Warrant [Member] | |||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.40 | ||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 8,615,384 | 8,615,384 | |||||||
Series F, Series G, and Series H Warrants [Member] | |||||||||
Class of Warrant or Right, Warrants Exercised (in shares) | 0 | 0 | 0 | 0 | |||||
The 2017 SPA [Member] | |||||||||
Registered Direct Offering, Maximum Amount | $ 50,000,000 | ||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 10,166,664 | ||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 0.60 | ||||||||
The 2018 SPA [Member] | |||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 9,070,000 | ||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 0.50 | ||||||||
The 2019 SPA [Member] | |||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 8,615,384 | ||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 0.325 |
Note 7 - Derivative Liabiliti_8
Note 7 - Derivative Liabilities (10Q) (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | |||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Sep. 30, 2021 | |
Derivative Liability, Total | $ 1,628,113 | ||||
Derivative Warrant Liability [Member] | |||||
Derivative Liability, Total | $ 1,628,113 | $ 1,628,113 | |||
Fair Value Adjustment of Derivatives | $ 0 | $ 0 | $ 0 | $ 108,944 | |
Series F Warrant [Member] | |||||
Class of Warrants and Rights, Required Cash Purchase Price (in dollars per share) | $ 0.18 | $ 0.18 | |||
Series G Warrant [Member] | |||||
Class of Warrants and Rights, Required Cash Purchase Price (in dollars per share) | 0.11 | 0.11 | |||
Series H Warrant [Member] | |||||
Class of Warrants and Rights, Required Cash Purchase Price (in dollars per share) | $ 0.0533 | $ 0.0533 |
Note 7 - Derivative Liabiliti_9
Note 7 - Derivative Liabilities - Fair Value of Derivative Liability (Details) - USD ($) | 9 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Sep. 30, 2021 | |
Issuances | $ 0 | |
Series F Warrant Derivative [Member] | Fair Value, Inputs, Level 3 [Member] | Derivative Financial Instruments, Liabilities [Member] | ||
Balance | 1,000,000 | $ 1,000,000 |
Issuances | 0 | |
Adjustments to estimated fair value | (1,000,000) | 0 |
Balance | 0 | 1,000,000 |
Series G Warrant Derivative [Member] | Fair Value, Inputs, Level 3 [Member] | Derivative Financial Instruments, Liabilities [Member] | ||
Balance | 748,275 | 748,275 |
Issuances | 0 | |
Adjustments to estimated fair value | 0 | 0 |
Balance | 748,275 | 748,275 |
Series H Warrant Derivative [Member] | Fair Value, Inputs, Level 3 [Member] | Derivative Financial Instruments, Liabilities [Member] | ||
Balance | 459,200 | 568,144 |
Issuances | 0 | |
Adjustments to estimated fair value | 0 | (108,944) |
Balance | $ 459,200 | $ 459,200 |
Note 7 - Derivative Liabilit_10
Note 7 - Derivative Liabilities - Derivative Liability Value Assumptions (Details) - Derivative Financial Instruments, Liabilities [Member] | Jun. 30, 2022 | Sep. 30, 2021 |
Measurement Input, Share Price [Member] | Series G Warrant Derivative [Member] | ||
Measurement Input | 0.046 | 0.12 |
Measurement Input, Share Price [Member] | Series H Warrant Derivative [Member] | ||
Measurement Input | 0.046 | 0.12 |
Measurement Input, Share Price [Member] | Series F Warrant Derivative [Member] | ||
Measurement Input | 0.12 | |
Measurement Input, Exercise Price [Member] | Series G Warrant Derivative [Member] | ||
Measurement Input | 0.70 | 0.70 |
Measurement Input, Exercise Price [Member] | Series H Warrant Derivative [Member] | ||
Measurement Input | 0.40 | 0.40 |
Measurement Input, Exercise Price [Member] | Series F Warrant Derivative [Member] | ||
Measurement Input | 0.75 | |
Measurement Input, Price Volatility [Member] | Series G Warrant Derivative [Member] | ||
Measurement Input | 1.0618 | 0.8740 |
Measurement Input, Price Volatility [Member] | Series H Warrant Derivative [Member] | ||
Measurement Input | 0.9585 | 0.8659 |
Measurement Input, Price Volatility [Member] | Series F Warrant Derivative [Member] | ||
Measurement Input | 0.9028 | |
Measurement Input, Risk Free Interest Rate [Member] | Series G Warrant Derivative [Member] | ||
Measurement Input | 0.0280 | 0.0019 |
Measurement Input, Risk Free Interest Rate [Member] | Series H Warrant Derivative [Member] | ||
Measurement Input | 0.0292 | 0.0041 |
Measurement Input, Risk Free Interest Rate [Member] | Series F Warrant Derivative [Member] | ||
Measurement Input | 0.0004 | |
Measurement Input, Expected Dividend Rate [Member] | Series G Warrant Derivative [Member] | ||
Measurement Input | 0 | 0 |
Measurement Input, Expected Dividend Rate [Member] | Series H Warrant Derivative [Member] | ||
Measurement Input | 0 | 0 |
Measurement Input, Expected Dividend Rate [Member] | Series F Warrant Derivative [Member] | ||
Measurement Input | 0 | |
Measurement Input, Expected Term [Member] | Series G Warrant Derivative [Member] | ||
Measurement Input | 0.94 | 1.70 |
Measurement Input, Expected Term [Member] | Series H Warrant Derivative [Member] | ||
Measurement Input | 1.83 | 2.58 |
Measurement Input, Expected Term [Member] | Series F Warrant Derivative [Member] | ||
Measurement Input | 0.34 |
Note 8 - October 2019 Registe_4
Note 8 - October 2019 Registered Direct Offering (Details Textual) - USD ($) | 9 Months Ended | ||
Oct. 18, 2019 | Jun. 30, 2022 | Jun. 30, 2021 | |
Series I Warrant [Member] | |||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | ||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.22 | ||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 14,285,714 | ||
October 2019 Placement Agent Warrants [Member] | |||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.21875 | ||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,071,429 | ||
Warrants and Rights Outstanding, Term (Year) | 5 years | ||
Series I and Placement Warrants [Member] | |||
Class of Warrant or Right, Warrants Exercised (in shares) | 0 | 0 | |
Placement Fees [Member] | |||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,071,429 | ||
October 2019 Registered Direct Offering [Member] | |||
Stock Issued During Period, Shares, New Issues (in shares) | 14,285,714 | ||
Shares Issued, Price Per Share (in dollars per share) | $ 0.175 | ||
Proceeds from Issuance or Sale of Equity, Total | $ 2,500,000 | ||
Payments of Stock Issuance Costs | $ 333,000 | ||
October 2019 Registered Direct Offering [Member] | Minimum [Member] | |||
Securities Purchase Agreement, Cash Placement Fee | 6% | ||
October 2019 Registered Direct Offering [Member] | Maximum [Member] | |||
Securities Purchase Agreement, Cash Placement Fee | 8.20% | ||
October 2019 Registered Direct Offering [Member] | Placement Fees [Member] | Wainwright [Member] | |||
Payments of Stock Issuance Costs | $ 158,000 |
Note 9 - 2021 Registered Dire_4
Note 9 - 2021 Registered Direct Offering (Details Textual) - USD ($) | 9 Months Ended | |
Feb. 11, 2021 | Jun. 30, 2022 | |
Series K Warrant [Member] | ||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 32,343,754 | 32,343,754 |
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.17 | |
Warrants and Rights Outstanding, Term (Year) | 5 years 6 months | |
Placement Agent 2 Warrants [Member] | ||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 3,234,375 | 3,234,375 |
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.20 | |
Warrants and Rights, Percent of Stock Oustanding Callable | 7.50% | |
Series K and Placement Agent 2 Warrants [Member] | ||
Class of Warrant or Right, Warrants Exercised (in shares) | 0 | |
The 2021 Registered Direct Offering [Member] | ||
Stock Issued During Period, Shares, New Issues (in shares) | 43,125,004 | |
Shares Issued, Price Per Share (in dollars per share) | $ 0.16 | |
Proceeds from Issuance or Sale of Equity, Total | $ 6,900,000 | |
Payments of Stock Issuance Costs | 700,000 | |
The 2021 Registered Direct Offering [Member] | Non-accountable Expense Fee [Member] | ||
Securities Purchase Agreement, Potential Fees | 10,000 | |
The 2021 Registered Direct Offering [Member] | Fees and Expenses of Legal Counsel and Other Out-of-pocket Expenses [Member] | ||
Securities Purchase Agreement, Potential Fees | 50,000 | |
The 2021 Registered Direct Offering [Member] | Clearing Expenses [Member] | ||
Securities Purchase Agreement, Potential Fees | $ 10,000 | |
The 2021 Registered Direct Offering [Member] | Participating Investors [Member] | ||
Securities Purchase Agreement, Cash Placement Fee | 7.50% | |
The 2021 Registered Direct Offering [Member] | Certain Investors With Pre-existing Relationships [Member] | ||
Securities Purchase Agreement, Cash Placement Fee | 6% |
Note 10 - Series 1 and Series_2
Note 10 - Series 1 and Series 2 Convertible Notes (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||
Jun. 22, 2020 | Jun. 04, 2020 | Jun. 03, 2020 | Jun. 30, 2022 | Jun. 30, 2022 | Jun. 30, 2021 | Sep. 30, 2021 | Sep. 30, 2020 | Nov. 06, 2020 | |
Proceeds from Warrant Exercises | $ 0 | $ 932,728 | |||||||
Series D Warrants [Member] | |||||||||
Proceeds from Warrant Exercises | $ 82,000 | $ 850,000 | |||||||
Class of Warrant or Right, Warrants Exercised (in shares) | 454,546 | ||||||||
Remaining Warrants [Member] | |||||||||
Class of Warrant or Right, Warrants Exercised (in shares) | 4,727,273 | ||||||||
Series J Warrants [Member] | |||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 340,910 | 3,545,454 | 3,375,000 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.25 | $ 0.25 | |||||||
Warrants and Rights Outstanding, Term (Year) | 1 year | 1 year | |||||||
Series 1 Convertible Notes [Member] | |||||||||
Debt Instrument, Interest Rate, Stated Percentage | 10% | ||||||||
Debt Instrument, Face Amount | $ 550,000 | ||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 0.27 | ||||||||
Series 1 Convertible Notes [Member] | Maximum [Member] | |||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 0.32 | ||||||||
Series 2 Convertible Notes [Member] | |||||||||
Debt Instrument, Face Amount | $ 1,050,000 | ||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 0.25 | ||||||||
Series 1 & 2 Convertible Notes [Member] | |||||||||
Interest Expense, Debt, Total | $ 40,000 | $ 120,000 | $ 110,000 |
Note 11 - Advances from Inves_2
Note 11 - Advances from Investors (Details Textual) - USD ($) | 9 Months Ended | |
Jun. 30, 2022 | Jun. 30, 2021 | |
Proceeds from Advances from Investors | $ 575,000 | $ 0 |
President and Chief Executive Officer, Chief Financial Officer, and Board of Directors [Member] | ||
Proceeds from Advances from Investors | $ 80,000 |
Note 12 - Payroll Protection _2
Note 12 - Payroll Protection Program Loan (Details Textual) | Apr. 25, 2020 USD ($) |
Paycheck Protection Program Loan [Member] | |
Proceeds from Issuance of Debt | $ 176,300 |
Note 14 - Subsequent Events (De
Note 14 - Subsequent Events (Details Textual) - USD ($) | 9 Months Ended | ||||
Jul. 07, 2022 | Jun. 30, 2022 | Jun. 30, 2021 | Nov. 06, 2020 | Jun. 04, 2020 | |
Proceeds from Advances from Investors | $ 575,000 | $ 0 | |||
Series 1 Convertible Notes [Member] | |||||
Debt Instrument, Face Amount | $ 550,000 | ||||
Debt Instrument, Interest Rate, Stated Percentage | 10% | ||||
Series 2 Convertible Notes [Member] | |||||
Debt Instrument, Face Amount | $ 1,050,000 | ||||
Subsequent Event [Member] | |||||
Percentage of Principal Amount | 15% | ||||
Proceeds from Issuance of Convertible Notes, Common Stock and Warrants, Gross | $ 3,500,000 | ||||
Proceeds from Advances from Investors | $ 600,000 | ||||
Subsequent Event [Member] | Securities Purchase Agreement [Member] | |||||
Stock Issued During Period, Shares, New Issues (in shares) | 12,766,600 | ||||
Subsequent Event [Member] | Notes 2022 [Member] | |||||
Proceeds from Issuance of Private Placement | $ 2,400,000 | ||||
Subsequent Event [Member] | Warrant Shares [Member] | |||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 85,110,664 | ||||
Subsequent Event [Member] | Notes 2022 [Member] | |||||
Debt Instrument, Face Amount | $ 4,230,000 | ||||
Debt Instrument, Unamortized Discount, Total | $ 710,000 | ||||
Subsequent Event [Member] | Series 1 Convertible Notes [Member] | |||||
Debt Instrument, Interest Rate, Stated Percentage | 10% | ||||
Subsequent Event [Member] | Series 2 Convertible Notes [Member] | |||||
Debt Instrument, Interest Rate, Stated Percentage | 10% | ||||
Debt Instrument, Failure to Complete Uplist Transaction Fee, Percentage of Outstanding Principal | 125% |